日本臨牀　65/増刊5　心不全　下

出版社： 日本臨牀社
発行日： 2007-05-28
分野： 臨床医学：一般  >  雑誌
雑誌名：
特集： 心不全　下　最新の基盤・臨床研究の進歩
電子書籍版： 2007-05-28 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

14,300 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

14,300 円(税込)

購入する

目次

  • 日本臨牀　65/増刊5　心不全　下

    ―目次―

    特集　心不全　下　最新の基盤・臨床研究の進歩

    XI． 心不全治療薬概論 　 　
    XII． 心不全治療薬併用療法 　 　
    XIII． 研究・開発中の薬物・治療法 　 　
    XIV． 機械的補助治療(内科領域) 　 　
    XV． 外科療法 　 　
    XVI． 血液浄化療法 　 　
    XVII． 輸液療法 　 　
    XVIII． 温熱療法 　 　
    XIX． 運動療法 　 　
    XX． 予後 　 　
    XXI． 危険因子・予防 　 　
    XXII． 管理・看護 　 　
    XXIII． 心不全での合併症−成因・病態・治療− 　 　
    XXIV． 心不全の原因疾患(基礎疾患)別の臨床的事項
    　　　　−病態，発症機序(心不全)，治療− 　 　
    XXV． その他病態・年齢層の心不全の臨床的事項 　 　
    XXVI． 特論

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

XI 心不全治療薬概論

P.12 掲載の参考文献
1) Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol 26 : 1376-1398, 1995.
 
2) Hunt SA, et al ; American College of Cardiology/American Heart Association : ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult ; executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure), J Am Coll Cardiol 38 : 2101-2113, 2001.
 
3) Hunt SA, et al ; Heart Rhythm Society : ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Circulation 112 : e154-235, 2005.
 
4) 日本循環器学会 : 慢性心不全治療ガイドライン. Jpn Circ J 64 (S4) : 1129-1165, 2000.
 
5) 日本循環器学会 : 慢性心不全治療ガイドライン (2005年改訂版), ダイジェスト版, p17-83, 2005.
 
6) Yusuf S, et al for INTERHEART Study lnvestigators : Effect of potentially modifiable risk factors associated With myocardial infarction in 52 countries (the INTERHEART study) : case-control study. Lancet 364 : 937-952, 2004.
PubMed
7) Chang PI, Pitt B : Theoretical basis for the use of angiotensin II antaganist in the treatment of heart faiure. Cardiologia 39 (Suupl 1) : 409, 1994.
 
8) Horiuchi M, et al : Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 33 : 613-621, 1999.
PubMed
9) Matsumori A : The Assessment of Response to Candesartan in Heart Failure in Japan (ARCH-J) Study Investigators : Ethcacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail 5 : 669-677, 2003.
 
10) McMurray JJV, et al : Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation 110 : 3281-3288, 2004.
PubMed
11) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
 
12) Pitt B, et al for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003.
 
13) 篠山重威 : わが国におけるspironolactoneの忍容性に関する調査研究. 心臓 37 : 644-651, 2005.
Medical*Online
14) Hori M, et al for the MUCHA Investigators : Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure. The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 147 : 324-330, 2004.
PubMed
15) Cohn JN, et al : Effect of vasodilator therapy on mortality in chronic congestive heart failure : results of a veterans Administration Cooperative Study. N Engl J Med 314 : 1547-1552, 1986.
 
16) Taylor AL, et al : Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 : 2049-2057, 2004.
PubMed
17) Sasayama S for OPC-8212 Multicenter Research Group : A Placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. Cardiovasc Drugs Ther 4 : 419-425, 1990.
 
18) Sasayama S for the EPOCH Study Group : Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure : The Effects of Pimobendan On Chronic Heart Failure Study. Circ J 66 : 149-157, 2002.
 
P.17 掲載の参考文献
1) Wasserstorm JA, Aistrup GL : Digitalis : new actions for an old drug. Am J physiol Heart Circ Physiol 289 : H1781-1793, 2005.
PubMed
2) Gheorghiade M, Ferguson D : Digoxin : a neurohumoral modulator in heart failure? Circulation 84 : 2181-2186, 1991.
PubMed
3) Ferguson DW, et al : Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation 80 : 65-67, 1989.
PubMed
4) Smith TW, et al : Digitalis glycosides : Mechanisms and manifestations of toxicity. Prog Cardiovasc Dis 26 : 413-458, 1984.
PubMed
5) Rahimtoola SH, Tak T : The use of digitalis in heart failure. Curr Probl Cardiol 21 : 781-853, 1996.
PubMed
6) Tsutamoto T, et al : Digitalis increases brain natriuretic peptide in patients with severe congestive heart failure. Am Heart J 134 : 910-916, 1997.
PubMed
7) Hunt SA, et al : ACC/AHA. 2005 guideline update for the diagnosis and management of chronic heart failure in the adult : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 112 : e154-e235, 2005.
 
8) Digitalis Investigation group : The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 : 525-533, 1997.
 
9) Khand AU, et al : Carvedilol alone or in combination with digoxin for the management of atrial fibrillation? J Am Coll Cardiol 42 : 1944-1951, 2003.
 
10) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure : Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
 
11) Uretsky BF, et al : Randomized study assessing the effect of digoxin Withdrawal in patients with mild to moderate chronic congestive heart failure : results of the PROVED trial. J Am Coll Cardiol 22 : 955-962, 1993.
 
12) Packer M, et al : Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitor. N Engl J Med 39 : 1-7, 1993.
 
13) Ward RE, et al : Economic outcomes of withdrawal of digoxin in therapy in adult patients with stable congestive heart failure. J Am Coll Cardiol 26 : 93-101, 1995.
PubMed
14) Ahmed A, et al : Effects of digoxin on morbidity and mortality in diastolic heart failure : the ancillary digitalis investigation group trial. Circulation 114 : 397-403, 2006.
PubMed
15) Digitalis Investigation Group : The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 : 525-533, 1997.
 
16) Adams KF Jr, et al : Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol 39 : 946-953, 2002.
PubMed
17) Rathore SS, et al : Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289 : 871-878, 2003.
PubMed
P.23 掲載の参考文献
1) Hussain Z, et al : Digoxin use of digoxin toxicity in the Post-DIG trial era. J Card Failure 12 : 343-348, 2004.
PubMed
2) Rahimtoola SH : Digitalis therapy for patients in clinical heart failure. Circulation 109 : 2942-2946, 2004.
PubMed
3) Uretsky BF, et al : Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure : results of the PROVED trial. J Am Coll Cardiol 22 : 955-962, 1993.
 
4) Packer M, et al : Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin converting enzyme inhibitors. N Engl J Med 329 : 1-7, 1993.
PubMed
5) The Digitalis Investigation Group : The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 : 525-533, 1997.
 
6) Eichhorn EJ, Gheorghiade M : Digoxin. Prog Cardiovasc Dis 44 : 251-266, 2002.
PubMed
7) Ahmed Ali, et al : Effects of digoxin on morbidity and mortality in diastolic heart failure : the ancillary digitalis investigation group trial. Circulation 114 : 397-403, 2006.
PubMed
8) Adams KF, et al : Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol 39 : 946-953, 2002.
PubMed
9) Rathore SS, et al : Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289 : 871-878, 2003.
PubMed
10) 循環器病の診断と治療に関するガイドライン (1998-1999年度合同研究班報告). 慢性心不全治療ガイドライン. Japanese Circulation Journal 65 : 841-861, 2001.
 
11) 循環器病の診断と治療に関するガイドライン (1998-1999年度合同研究班報告). 急性重症心不全治療ガイドライン. Japanese Circulation Journal 65 : 869-880, 2001.
 
12) Bristow MR, et al : Drugs in the treatment of heart failure. In : Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine (ed by Zipes DP, et al), 7th ed, p 581, Elsevier Saunders, Philadelphia, 2004.
 
P.28 掲載の参考文献
1) Bristow MR, et al : Drugs in the treatment of heart failure. In : Heart Disease, 7th ed (ed by Braunwald E, et al), p 569-601, Elsevier Saunders, Philadelphia, 2005.
 
2) Hastillo A, et al : Dobutamine. In : Cardiovascular Drug Therapy, 2nd ed (ed by Messerli FH), p1151-1161, WB Saunders, Philadelphia, 1996.
 
3) Murphy MD, et al : Dopamine. In : Cardiovascular Drug Therapy, 2nd ed (ed by Messerli FH), p1162-1177, WB Saunders, Philadelphia, 1996.
 
4) Port JD, et al : Neurotransmitter depletion compromises the ability of indirect-acting amines to provide inotropic support in the failing human heart. Circulation 81 : 929-938, 1990.
PubMed
5) Hoffman BB : Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In : Goodman and Gilman' s the Pharmacological Basis of Therapeutics, 11th ed (ed by Brunton LL, et al), p 237-276, The McGraw-Hill, New York, 2006.
 
6) Fawcett J : Physician's Drug Handbook, 8th ed, Springhouse, Pennsylvania, 1999.
 
7) 日本医薬品集フォーラム. 日本医薬品集2006年版 (高久文麿ほか監), じほう, 2006.
 
8) Loeb HS, et al : Superiority of dobutamine over dopamine for augmentation of cardiac output in patients with chronic low output cardiac failure. Circulation 55 : 375-378, 1977.
PubMed
9) Francis GS, et al : Comparative hemodynamic effects of dopamine and dobutamine in patients with acute cardiogenic circulatory collapse. Am Heart J 103 : 995-1000, 1982.
PubMed
10) Federico D, et al : Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation 74 (Suppl II) : II-38, 1986.
 
P.33 掲載の参考文献
1) Silver MA, et al : Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 39 : 798-803, 2002.
PubMed
2) Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF) : Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure : a randomized controlled trial. JAMA 287 : 1531-1540, 2002.
PubMed
3) 梶本克也ほか : 急性心不全または慢性心不全急性増悪に対するカルペリチドの有効性について. 心臓 36 : 66-69, 2004.
 
4) Braun World E, et al : Heart Disease, 6th ed, p 575-579, WB Saunders, Philadelphia, 2001.
 
5) 日本循環器学会 : 急性心不全治療ガイドライン. Jpn Circ J 64 (suppl IV) : 1129-1165, 2000.
 
6) Marik PE : Low-dose dopamine : a systematic review. Intensive Care Med 28 : 877-883, 2002.
PubMed
7) Richard C, et al : Combined hemodynamic effects of dopamine and dobutamine in cardiogenic shock. Circulation 67 : 620-626, 1983.
PubMed
8) Hunt SA ; American College of Cardiology ; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure : ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. J Am Coll Cardiol 46 : e1-e82, 2005.
 
P.38 掲載の参考文献
1) Cosin J, Diez J : Torasemide in chronic heart failure : results of the TORIC study. Eur J Heart Fail 4 : 507-513, 2002.
PubMed
2) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart fallure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
 
3) Pitt B, et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003.
PubMed
4) Kangawa K, Matsuo H : Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochem Biophys Res Commun 118 : 131-139, 1984.
PubMed
5) Opie L : Drugs for the Heart, 6th ed, Elsevier, Saunders, 2005.
 
P.42 掲載の参考文献
1) Braunwald E, Grossmann W : Heart Disease, 4th ed (ed by Braunwald E, et al), p 393-418, WB Saunders, Philadelphia, 1992.
 
2) Dormans TP, et al : Diuretic efficacy of high dose furosemide in severe heart failure : bolus injection versus continuous infusion. J Am Coll Cardiol 28 : 376-382, 1996.
PubMed
3) Adin DB, et al : Intermittent bolus injection versus continuous infusion of furosemide in normal adult greyhound dogs. J Vet Intern Med 17 : 632-636, 2003.
 
4) Ellison DH : Diuretic therapy and resistance in congestive heart failure. Cardiology 96 : 132-143, 2001.
PubMed
5) Cosin J, et al ; TORIC investigators : Toracemide in chronic heart failure : results of the TORIC study. Eur J Heart Fail 4 : 507-513, 2002.
 
6) Uchida T, et al : Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 205 : 145-150, 1991.
PubMed
7) Pitt B, et al ; Randomized Aldactone Evaluation Study Investigators : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 : 709-717, 1999.
PubMed
8) Pitt B, et al ; Eplerenone Post-Acute Myocardial Infraction Heart Failure Eflicacy and Survival Study Investigators : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003.
 
9) Weber Kr, Brilla CG : Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83 : 1849-1865, 1991.
 
10) Rajagopalan S, et al : Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105 : 2212-2216, 2002.
PubMed
11) Harada E, et al : Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 104 : 137-139, 2001.
PubMed
12) Struthers AD : Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 16 (Suppl N) : 103-106, 1995.
 
P.47 掲載の参考文献
1) Felker GM, et al : Heart failure etiology and response to milrinone in decompensated heart failure : results from the OPTIME-CHF study. J Am Coll Cardiol 41 : 997-1003, 2003.
PubMed
2) Nohria A, et al : Clinical assessment identifies hemodynamics profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 41 : 1797-1804, 2003.
PubMed
3) Sato N, et al : Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure. Am J Physiol 276 : H1699-1705, 1999.
PubMed
4) Sato N, et al : Arterial baroreflex sensitivity is a good predictor of inotropic responses to a phosphodiesterase inhibitor in human heart failure. Clin Cardiol 29 : 263-267, 2006.
PubMed
5) Baruch L, et al : Pharmacodynamic effects of milrinone with and without a bolus loading infusion. Am Heart J 141 : 266-273, 2001.
PubMed
6) HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Cardiac Fail 12 : e1-e122, 2006.
PubMed
7) Taniguchi T, et al : Pharmacokinetics of milrinone in patients with congestive heart failure during continuous venovenous hemofiltration. Intensive Care Med 26 : 1089-1093, 2000.
PubMed
8) Edelson J, et al : Pharmacokinetics of the bipyridines amrinone and milrinone. Circulation 73 : III145-152, 1986.
PubMed
9) Atarashi H, et al : A phase I study of E-1020-Intravenous injection. Jpn J Clin Pharmacol Ther 21 : 613-621, 1990.
 
10) Amenomori H, et al : Phosphodiesterase III inhibitor olprinone chlorate is not signhicantly removed by continuous venovenous hemofiltration. ASAIO J 46 : 635-638, 2000.
PubMed
11) Shigematsu A, et al : Phase I study of a heart failure drug, pimobendan capsules (UD-CG 115BS) : single oral doses of 1.25 mg, 2.5 mg, 5.0 mg, and 7.5 mg. Rinsyo to Kenkyu 68 : 2154-2172, 1991 (in Japanese).
 
12) Wakaumi M, et al : Plasma concentration profile of orally administered pimobendan and plasma brain natHuretic peptide level in patients with severe heart failure. Cardiovasc Drugs Ther 17 : 291-293, 2003.
PubMed
13) The task force on acute heart failure of the European society of cardiology : Guidelines on the diagnosis and treatment of acute heart failure. Eur Heart J e1-e36, 2005.
 
14) Cuffe MS, et al : Short-time intravenous milrinone for acute exacerbation of chronic heart failure : a randomized controlled trial. JAMA 287 : 1541-1547, 2002.
 
15) Felker GM, et al : Heart failure etiology and response to milrinone in decompensated heart failure : results from the OPTIME-CHF investigators. J Am Col Cardiol 41 : 997-1003, 2003.
 
16) Biddle TL, et al : Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. Am J Cardiol 59 : 1345-1350, 1987.
PubMed
17) Eichhron EJ, et al : Differential effects of milrinone and dobutamine on right ventricular preload, afterload and systolic performance in congestive heart failure secondary to ischemic of idiopathic dilated cardiomyopathy. Am J Cardiol 60 : 1329-1333, 1987.
 
18) The pimobendan in congestive heart failure (PICO) investigators : Effect of pimobendan on exercise capacity in patients with heart failure : main results from the pimobendan in congestive heart failure (PICO) trial. Heart 76 : 223-231, 1996.
 
19) The EPOCH study group : Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure-the effects of pimobendan on chronic heart failure study (EPOCH Study) -. Circ J 66 : 149-157, 2002.
 
20) Perrone SV, Kaplinsky EJ : Calcium sensitizer agents : A new class of inotropic agents in the treatment of decompensated heart failure. Int J Cardiol 103 : 248-255, 2005.
PubMed
P.55 掲載の参考文献
1) Monrad ES, et al : Improvement in indexes of diastolic performance in patients With congestive heart failure treated with milrinone. Circulation 70 : 1030-1037, 1984.
PubMed
2) Williams JF Jr, et al : ACC/AHA Task Force Report. Guidelines for evaluation and management of heart failure. Circulation 92 : 2764-2784, 1995.
 
3) 竹越嚢ほか : 急性重症心不全治療ガイドライン. Jpn Circ J 64 (Suppl IV) : 1129-1165, 2000.
 
4) Nieminen MS, et al ; ESC Committe for Practice Guideline (CPG) : Executive summary of the guidelines on the diagnosis and treatment of acute heart failure : the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 26 : 384-416, 2005.
 
5) 丸山幸夫ほか : 急性心不全治療ガイドライン (2006年改訂版). 日本循環器学会会員限定ホームページ (https://center.umin.ac.jp/oasis/jcs/supplement/index. htm).
 
6) 後藤葉一 : ホスホジエステラーゼ阻害薬をどのように使うか. 新・心臓病診療プラクティス. 心不全に挑む・患者を求う (筒井裕之ほか編), p232-238, 文光堂, 2005.
 
7) Kumar A, et al : Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. Am Heart J 142 : 512-515, 2001.
PubMed
8) Loh E, et al : A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure. J Card Fail 7 : 114-121, 2001.
 
9) Aranda JM Jr, et al : Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation : a prospective, randomized trial. Am Heart J 145 : 324-329, 2003.
PubMed
10) Cuffe MS, et al ; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators : Short-term intravenous milrinone for acute exacerbation of chronic heart failure : a randomized controlled trial. JAMA 287 : 1541-1547, 2002.
PubMed
11) Felker GM, et al ; OPTIME-CHF Investigators : Heart failure etiology and response to milrinone in decompensated heart failure : results from the OPTIME-CHF study. J Am Coll Cardiol 41 : 997-1003, 2003.
PubMed
12) Kanda M, et al : Diuretic effect of phosphodiesterase inhibitors depends on baseline renal function in patients with congestive heart failure. Am J Cardiol 83 : 1274-1277, 1999.
PubMed
13) Marius-Nunez AL, et al : Intermittent inotropic therapy in an outpatient setting : a cost-effective therapeutic modality in patients with refractory heart failure. Am Heart J 132 : 805-808, 1996.
 
14) Cesario D, et al : Beneficial effects of intermmittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure : a preliminary study. Am Heart J 135 : 121-129, 1998.
PubMed
15) Givertz MM, et al : Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction : a rapid test for reversibility of pulmonary hypertension. J Am Coll Cardiol 28 : 1775-1780, 1996.
PubMed
P.60 掲載の参考文献
1) Eriksson H, et al : Risk factors for heart failure in the general population : The study of men born in 1913. Eur Heart J 10 : 647-656, 1989.
 
2) The Pimobendan in Congestive Heart Failure (PICO) Investigators : Effect of pimobendan on exercise capacity in patients with heart failure : main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 76 : 223-231, 1996.
 
3) Sasayama S for the Effects of Pimobendan on Chronic Heart Failure (EPOCH) Study Group : Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure : the effects of pimobendan on chronic heart failure study (EPOCH study). Circ J 66 : 149-157, 2002.
 
4) Follath F, et al : Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study) : randomized double-blind trial. Lancet 360 : 196-202, 2002.
PubMed
5) Moiseyev VS, et al ; on behalf of RUSSLAN study investigators : Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction ; a randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23 : 1422-1432, 2002.
 
P.65 掲載の参考文献
1) Perrone SV, Kaplinsky EJ : Calcium sensitizer agents : A new class of inotropic agents in the treatment of decompensated heart failure. Int J Cardiol 103 : 248-255, 2005.
PubMed
2) Brixius K, et al : Ca2+ -sensitisers-a promising option to treat heart failure? Cardiovasc Drugs Ther 19 : 423-428, 2005.
 
3) The PRO MISE Study Research Group : Effects of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325 : 1468-1475, 1991.
 
4) Hagemeijer F, et al : Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 63 : 571-576, 1989.
PubMed
5) Lubsen J, et al : Effect of pimobendan on exercise capacity in patients with heart failure : main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 76 : 223-231, 1996.
PubMed
6) The EPOCH Study Group : Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure : the effects of pimobendan on chronic heart failure (EPOCH study). Circ J 66 : 149-157, 2002.
 
7) Takaoka H, et al : Beneficial effects of a Ca2+sensitizer, MCI-154, 0n the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction : comparison with dobutamine and phosphodiesterase inhibitor. Am Heart J 133 : 283-289, 1997.
 
8) Follath F, et al : Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study) : a randomised double-blind trial. Lancet 360 : 196-202, 2002.
PubMed
9) Moiseyev VS, et al : Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23 : 1422-1432, 2002.
 
10) Cleland JG, et al : Clinical trials update and cumulative meta-analyses from the American College of Cardiology : WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 6 : 501-508, 2004.
 
P.70 掲載の参考文献
1) Dzau V, Braunwald E : Resolved and unresolved issues in the prevention and treatment of coronary artery disease : a workshop consensus statement. Am Heart J 121 : 1244-1263, 1991.
PubMed
2) Neal B, et al ; Blood Pressure Lowering Treatment Trialists' Collaboration : Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs : results of prospectively designed overviews of randomised trials. Lancet 356 (9246) : 1955-1964, 2000.
PubMed
P.77 掲載の参考文献
1) The CONSENSUS trial study group : Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 : 1429-1435, 1987.
 
2) Cohn JN, et al : A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 : 303-310, 1991.
PubMed
3) The SOLVD investigators : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 : 293-302, 1991.
PubMed
4) Yusuf S, et al : Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 : 145-153, 2000.
 
5) The EUROPA investigators : Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease : randomised, double-blind, placebo-controlled, multicentre trial (the EURO PA study). Lancet 362 : 782-788, 2003.
 
6) Hunt SA, et al : ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult : Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure) : Developed in Collaboration With the International Society for Heart and Lung Transplantation ; Endorsed by the Heart Failure Society of America. Circulation 104 : 2996-3007, 2001.
 
7) Pfeffer MA, et al : Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 : 669-677, 1992.
 
8) Cohn JN, Tognoni G : A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 : 1667-1675, 2001.
PubMed
9) Pfeffer MA, et al : Effects of candesartan on mortality and morbidity in patients with chronic heart failure : the CHARM-Overall programme. Lancet 362 : 759-766, 2003.
PubMed
10) Pfeffer MA, et al : Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 : 1893-1906, 2003.
 
P.83 掲載の参考文献
1) Kim S, Iwao H : Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52 (1) : 11-34, 2000.
PubMed
2) Hoieggen A, et al : The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 65 (3) : 1041-1049, 2004.
PubMed
3) Pitt B, et al : Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure : randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355 (9215) : 1582-1587, 2000.
PubMed
4) Dickstein K, Kjekshus J : Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction : the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360 (9335) : 752-760, 2002.
PubMed
5) Zou Y, et al : Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 6 (6) : 499-506, 2004.
PubMed
6) Pfeffer MA, et al : Effects of candesartan on mortality and morbidity in patients with chronic heart failure : the CHARM-Overall programme. Lancet 362 (9386) : 759-766, 2003.
PubMed
7) Cohn JN, Tognoni G : A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (23) : 1667-1675, 2001.
PubMed
8) Pfeffer MA, et al : Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (20) : 1893-1906, 2003.
 
9) Schupp M, et al : Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109 (17) : 2054-2057, 2004.
PubMed
P.88 掲載の参考文献
1) Pitt B, et al : Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349 : 747-752, 1997.
PubMed
2) Pitt B, et al : Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure : randomised trial-the losartan heart failure survival study ELITE II. Lancet 355 : 1582-1587, 2000.
PubMed
3) Cohn JN, et al : A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 : 1667-1675, 2001.
PubMed
4) Pfeffer MA, et al : Effects of candesartan on mortality and morbidity in patients with chronic heart failure : the CHARM-Overall programme. Lancet 362 : 759-766, 2003.
PubMed
5) The SOLVD Investigators : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 : 293-302, 1991.
PubMed
6) Packer M, et al : Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 100 : 2312-2318, 1999.
PubMed
7) Balcells E, et al : Angiotensin II formation from ACE and chymase in human and animal hearts : methods and species considerations. Am J Physiol 273 : H1769-1774, 1997.
PubMed
8) Zou Y, et al : Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 6 : 499 -506, 2004.
 
9) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult.
 
10) Young JB, et al : Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction : results of the CHARM low-left ventricular ejection fraction trials. Circulation 110 : 2618-2626, 2004.
PubMed
P.97 掲載の参考文献
1) Waagstein F, et al : Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37 : 1022-1036, 1975.
PubMed
2) Packer M, et al for the US carvedilol heart failure study group : The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 : 1349-1355, 1996.
 
3) Packer M, et al for the carvedilol prospective randomized cumulative survival study group : Efiiect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 : 1651-1658, 2001.
 
4) Hori M, et al on behalf of the MUCHA investigators : Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure ; the multicenter carvedilol heart failure dose assessment (MUCHA) trial. Am Heart J 147 : 324-330, 2004.
 
5) Waagstein F, et al for the metoprolol in dilated cardiomyopathy (MDC) trial study group : Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342 : 1441-1446, 1993.
 
6) MERIT-HF study group : Effect of metoprolol CR/XL in chronic heart failure ; metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353 : 2001-2007, 1999.
 
7) CIBIS investigators and committees : A randomized trial of i9-blockade in heart failure ; the cardiac insufficiency bisoprolol study (CIBIS). Circulation 90 : 1765-1773, 1994.
 
8) CIBIS-II investigators and committees : The cardiac insufficiency bisoprolol study II (CIBIS-II) ; a randomised trial. Lancet 353 : 9-13, 1999.
 
9) The RESOLVD Investigators : Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 101 : 378-384, 2000.
 
10) Reiken S, et al : Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 107 : 2459-2466, 2003.
PubMed
11) Ohtsuka T, et al : Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 89 : 996-999, 2002.
PubMed
12) Flesch M, et al : Efifect of beta-blockers on free radical-induced cardiac contractile dysfunction. Circulation 100 : 346-353, 1999.
 
13) Shelton RJ, et al : Effect of a community heart failure clinic on uptake of beta blockers by patients with obstructive airways disease and heart failure. Heart 92 : 331-336, 2006.
PubMed
14) Bakris GL, et al for the GEMINI investigators : Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension : a randomized controlled trial. JAMA 292 : 2227-2236, 2004.
PubMed
P.101 掲載の参考文献
1) Gattis WA, et al : Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. J Am Coll Cardiol 43 : 1534-1541, 2004.
PubMed
2) Heart Failure Society of America : Executive summary : HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 12 : 10-38, 2006.
 
3) Yoshikawa T, et al : Effectiveness of carvedilol-alone versus-carvedilol+pimobendan for severe congestive heart failure. Am J Cardiol 85 : 1495-1497, 2000.
PubMed
4) 吉川勉 : β遮断薬のインバース・アゴニズム作用. 呼吸と循環 54 : 1105-1109, 2006.
 
5) 吉川勉 : β遮断薬とインバースアゴニズム. 医学のあゆみ 218 : 1251-1256, 2006.
 
6) Kotlyar E, et al : Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transpl 21 : 1290-1295, 2002.
PubMed
7) Yoshizawa A, et al : Brain natriuretic peptide response is heterogeneous during β-blocker therapy for congestive heart failure. J Card Fail 10 : 310-315, 2004.
 
8) Davis ME, et al : Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 113 : 977-985, 2006.
PubMed
9) Metra M, et al : Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure. J Am Coll Cardiol 40 : 1248-1258, 2002.
PubMed
10) Bergsrom A, et al : Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Eur J Heart Fail 6 : 453-461, 2004.
PubMed
11) Flather MD, et al : Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 : 215-225, 2005.
PubMed
12) Ghio S, et al : Effects of nebivolol in elderly heart failure patients with or Without systolic left ventricular dysfunction : results of the SENIORS echocardiographic substudy. Eur Heart J 27 : 562-568, 2006.
 
13) Willenheimer R, et al : Effect of survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence. Circulation 112 : 2426-2435, 2005.
PubMed
P.106 掲載の参考文献
1) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
 
2) Pitt B, et al ; Eplerenone Post-Acute Myocardial Infraction Heart Failure Efficacy and Survival Study Investigators : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003.
 
3) Delcayre C, et al : Cardiac aldosterone production and ventricular remodeling. Kidney Int 57 : 1346-1351, 2000.
PubMed
4) Brown NJ : Eplerenone : cardiovascular protection. Circulation 107 : 2512-2518, 2003.
PubMed
5) Lopez B, et al : Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 43 : 2028-2035, 2004.
PubMed
P.109 掲載の参考文献
1) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 : 709-717, 1999.
PubMed
P.114 掲載の参考文献
1) 武田憲文, 平田恭信 : 心不全 : 診断と治療の進歩 5. 心房性ナトリウム利尿ペプチド. 日内会誌 94 : 270-275, 2005.
 
2) Kangawa K, Matsuo H : Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochem Biophys Res Commun 118 : 131-139, 1984.
PubMed
3) Lopez MJ, et al : Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natHuretic peptide. Nature 378 : 65-68, 1995.
PubMed
4) John SW, et al : Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 267 : 679-681, 1995.
PubMed
5) Kimura K, et al : Effects of atrial natriuretic peptide on renal arterioles : morphometric analysis using microvascular casts. Am J Physiol 259 : F936-944, 1990.
PubMed
6) Holtwick R, et al : Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 111 : 1399-1407, 2003.
 
7) Nakanishi M, et al : Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice. Hypertension 46 : 441-447, 2005.
PubMed
8) Murakawa Y, et al : Effect of atrial natriuretic peptide on electrical defibrillation efficacy. J Cardiovasc Electrophysiol 9 : 962-969, 1998.
PubMed
9) Kasahara M, et al : Ameliorated glomerular injury in mice overexpressing brain natriuretic peptide with renal ablation. J Am Soc Nephrol 11 : 1691-1701, 2000.
PubMed
10) Saito Y, et al : Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure : beneficial effects on left ventricular function. Circulation 76 : 115-124, 1987.
PubMed
11) Asakura M, et al : Rationale and design of a large-scale trial using atrial natriuretic peptide (ANP) as an adjunct to percutaneous coronary intervention for st-segment elevation acute myocardial infarction-Japan-Working Groups of Acute Myocardial Infraction for the Reduction of Necrotic Damage by ANP (J-WIND-ANP) -. Circ J 68 : 95-100, 2004.
 
12) Sward K, et al : Recombinant human atrial natriuretic peptide in ischemic acute renal failure : A randomized placebo-controlled trial. Crit Care Med 32 : 1310-1315, 2004.
PubMed
13) Topol EJ : Nesiritide-Not verified. N Engl J Med 353 : 113-116, 2005.
PubMed
14) Riter HG : Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol 47 : 2334-2335, 2006.
PubMed
P.119 掲載の参考文献
1) Kangawa K, et al : Purification and complete amino acid sequence ofα-human atrial natriuretic polypeptide (α-hANP). Biochem Biophys Res Commun 118 : 131-139, 1984.
 
2) Nakao K, et al : Molecular biology and biochemistry of the natriuretic peptide system. I : Natriuretic peptides. J Hypertens 10 : 907-912, 1992.
PubMed
3) Mukoyama M, et al : Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med 323 : 757-758, 1990.
PubMed
4) Saito Y, et al : Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure : beneficial effects on left ventricular function. Circulation 76 : 115-124, 1987.
PubMed
5) Asakura M, et al : Rationale and design of a large-scale trial using atrial natriuretic peptide (ANP) as an adjunct to percutaneous coronary intervention fbr ST-segment elevation acute myocardial infarction : Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage by ANP (J-WIND-ANP). Circ J 68 (2) : 95-100, 2004.
 

XII 心不全治療薬併用療法

P.126 掲載の参考文献
1) Rousseau M, et al : Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long term therapy with angiotensin converting enzyme inhibitor. Am J Cardiol 73 : 488-493, 1994.
PubMed
2) Pitt B, et al : Randomised trial of losartan versus captopril in patients with over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349 : 747-752, 1997.
PubMed
3) Dickstein K, et al ; the OPTImn Steering Committee : Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction : the OPTIMAAL randomized trial. Lancet 360 : 752-760, 2002.
 
4) Tsutsui H, et al : Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol 88 : 530-533, 2001.
PubMed
5) Ohkubo T, et al : Control of blood pressure as measured at home and office, and comparison with physicians' assessment of control among treated hypertensive patients in Japan : First Report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study. Hypertens Res 27 (10) : 755-763, 2004.
PubMed
6) Cohn JN, et al : A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 : 1667-1675, 2001.
PubMed
7) McMurray JJV, et al : Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors : the CHARM-Added trial. Lancet 362 : 767-771, 2003.
PubMed
8) Chobanian AV, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure : the JNC 7 report. JAMA 289 : 2560-2572, 2003.
PubMed
9) Conlin PR, et al : Angiotensin II antagonists for hypertension : Are there differences in efficacy? Am J Hypertens 13 : 418-426, 2000.
PubMed
P.133 掲載の参考文献
1) 慢性心不全治療ガイドライン (2005年改訂版), 日本循環器学会・合同研究班 (https://center.umin.ac.jp/oasis/jcs/supplement/rev2004/index.htm).
 
2) Hunt SA, et al : ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation 112 : e154-235, 2005.
PubMed
3) Packer M, et al : Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 : 1651-1658, 2001.
PubMed
4) Willenheimer R, et al : Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enarapril, as compared with the opposite sequence. Results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 112 : 2426-2435, 2005.
 
5) The NETWORK investigators : Clinical outcome with enalapril in symptomatic chronic heart failure ; adose comparison. Eur Heart J 19 : 481-489, 1998.
 
6) Packer M, et al : Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 100 : 2312-2318, 1999.
PubMed
7) Cohn JN, Tognoni G ; Valsartan Heart Failure Trial Investigators : A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 : 1667-1675, 2001.
 
8) McMurray JJ, et al : Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors : the CHARM-Added trial. Lancet 362 : 767-771, 2003.
PubMed
9) Davis ME, et al : Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 113 : 977-985, 2006.
PubMed
10) Metra M, et al : Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure : a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 40 : 1248-1258, 2002.
PubMed
11) Bollano E, et al : Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure. Heart 89 : 621-624, 2003.
PubMed
12) Shakar SF, et al : Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class W heart failure. J Am Coll Cardiol 31 : 1336-1340, 1998.
 
13) Kumar A, et al : Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. Am Heart J 142 : 512-515, 2001.
PubMed
14) Yoshikawa T, et al : Effectiveness of carvedilol alone versus carvedilol+pimobendan for severe congestive heart failure. For the Keio Interhospital Cardiology Study (KICS) Group. Am J Cardiol 85 : 1495-1497, 2000.
 
P.138 掲載の参考文献
1) Shipley JB, et al : Milrinone : basic and clinical pharmacology and acute and chronic management. Am J Med Sci 311 : 286-291, 1996.
PubMed
2) Polanczyk CA, et al : Ten-year trends in hospital care for congestive heart failure : improved outcomes and increased use of resources. Arch Intern Med 160 : 325-332, 2000.
PubMed
3) Lowes BD, et al : Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiology 81 : 141-149, 2001.
 
4) Follath F, et al ; Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study : Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study) : a randomised double-blind trial. Lancet 360 : 196-202, 2002.
 
5) Felker GM, et al ; OPTIME-CHF Investigators : Heart failure etiology and response to milrinone in decompensated heart failure, results from the OPTIME-CHF study. J Am Coll Cardiol 41 : 997-1003, 2003.
PubMed
6) Gage J, et al : Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation 74 : 367-373, 1986.
PubMed
7) Nanas JN, et al : Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Am J Cardiol 94 : 1329-1332, 2004.
PubMed
8) Jhaveri R, et al : Enhanced vasodilatory responses to milrinone in catecholamine-precontracted small pulmonary arteries. Anesth Analg 98 : 1618-1622, 2004.
PubMed
9) 梶本克也ほか : 急性心不全に強心剤を使うべき. 呼吸と循環 52 : 897-902, 2004.
 
P.143 掲載の参考文献
1) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316 : 1429-1435, 1987.
 
2) Cohn JN, et al : A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 : 303-310, 1991.
PubMed
3) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 327 : 685-691, 1992.
PubMed
4) Pitt B, et al : Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure : randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355 : 1582-1587, 2000.
PubMed
5) McKelvie RS, et al : Comparison of candesartan, enalapril, and their combination in congestive heart failure : randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study lnvestigators. Circulation 100 : 1056-1064, 1999.
PubMed
6) Cohn JN, Tognoni G ; Valsartan Heart Failure Trial Investigators : A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 : 1667-1675, 2001.
 
7) McMurray JJ, et al ; CHARM Investigators and Committees : Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-convertingenzyme inhibitors : the CHARM-Added trial. Lancet 362 : 767-771, 2003.
 
8) Dickstein K, Kjekshus J ; OPTIMAAL Steering Committee of the OPTIMAAL Study Group : Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction : the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360 : 752-760, 2002.
 
9) Pfeffer MA, et al ; Valsartan in Acute Myocardial Infraction Trial Investigators : Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 : 1893-1906, 2003.
 
10) Hunt SA ; American College of Cardiology ; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) : ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaldation and Management of Heart Failure). J Am Coll Cardiol 46 : e1-e82, 2005.
 
11) Swedberg K, et al ; Task Froce for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology : Guidelines for the diagnosis and treatment of chronic heart failure : executive summary (update 2005) : The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 : 1115-1140, 2005.
 
12) Arnold JM, et al ; Canadian Cardiovascular Society : Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006 : diagnosis and management. Can J Cardiol 22 : 23-45, 2006.
 
13) Heart Failure Society Of America : Executive summary : HFSA Comprehensive Heart Failure Practice Guideline. J Card Fail 12 : 10-38, 2006.
 
P.148 掲載の参考文献
1) Rocha R, Funder JW : The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 970 : 89-100, 2002.
PubMed
2) Pitt B : "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor : implications for therapy. Cardiovasc Drugs Ther 9 : 145-149, 1995.
PubMed
3) McKelvie RS, et al : Comparison of candesartan, enalapril, and their combination in congestive heart failure : randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study lnvestigators. Circulation 100 : 1056-1064, 1999.
PubMed
4) Swedberg K, et al : Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group. Am J Cardiol 66 : 40D-44D, 1990.
 
5) Domanski M, et al : Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 42 : 705-708, 2003.
PubMed
6) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
 
7) Pitt B, et al ; Eplerenone Po st-Acute Myocardial Infraction Heart Failure Efiicacy and Survival Study Investigators : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003.
 
8) Pitt B : Effect of aldosterone blockade in patients with systolic left ventricular dysfunction : implications of the RALES and EPHESUS studies. Mol Cell Endocrinol 217 : 53-58, 2004.
PubMed
9) Pitt B, et al ; EPHESUS Investigators : Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 46 : 425-431, 2005.
PubMed
10) Juurlink DN, et al : Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 : 543-5512004.
PubMed
11) Shah KB, et al : The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol 46 : 845-849, 2005.
PubMed
12) Schepkens H, et al : Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone : an analysis of 25 cases. Am J Med 110 : 438-441, 2001.
PubMed
13) Tamirisa KP, et al : Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 148 : 971-978, 2004.
PubMed
14) Sato A, et al : Eiifects of spironolactone and angiotensin-convening enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 22 : 17-22, 1999.
 
15) Sato A, et al : Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res 29 : 211-216, 2006.
PubMed
16) Taniguchi I, et al : Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. Circ J 70 : 995-1000, 2006.
PubMed
17) Matsumoto R, et al : Effects of aldosterone receptor antagonist and angiotensin II type I receptor blocker on cardiac transcriptional factors and mRNA expression in rats with myocardial infarction. Circ J 68 : 376-382, 2004.
PubMed
18) Fraccarollo D, et al : Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction. Cardiovasc Res 67 : 97-105, 2005.
PubMed

XIII 研究・開発中の薬物・治療法

P.158 掲載の参考文献
1) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 : 709-717, 1999.
PubMed
2) Pitt B, et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (14) : 1309-1321, 2003.
PubMed
3) Pitt B, et al : Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy : the 4 E-left ventricular hypertrophy study. Circulation 108 (15) : 1831-1838, 2003.
 
4) Krum H, et al : Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 40 : 117-123, 2002.
PubMed
P.163 掲載の参考文献
1) Benigni A, Remuzzi G : Endothelin antagonists. Lancet 353 : 133-138, 1999.
PubMed
2) Neidhart W, et al : The discovery of non-peptide endothelin receptor antagonist. Progression towards bosentan. Chimia 50 : 519-524, 1996.
 
3) Clozel M, et al : Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 270 : 228-235, 1994.
PubMed
4) Weber C, et al : Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 60 : 124-137, 1996.
PubMed
5) Giaid A, et al : Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328 : 1732-1739, 1993.
PubMed
6) MacLean MR : Endothelin-1 : a mediator of pulmonary hypertension? Pulm Pharmacol Ther 11 : 125-132, 1998.
PubMed
7) Roux S, et al : Endothelin antagonism with bosentan : a review of potential applications. J Mol Med 77 : 364-376, 1999.
PubMed
8) Channick RN, et al : Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension : a randomised placebo-controlled study. Lancet 358 : 1119-1123, 2001.
PubMed
9) Rubin U, et al : Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 : 896-903, 2002.
 
10) Sutsch G, et al : Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 98 : 2262-2268, 1998.
PubMed
11) Mylona P, Cleland JG : Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio. net Editorial Team. Eur J Heart Fail 1 : 197-200, 1999.
 
12) Teerlink JR : Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE) : approaching the asymptote of efficacy? J Card Fail 8 : 124-127, 2002.
PubMed
P.167 掲載の参考文献
1) Cooper HA, et al : Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 100 : 1311-1315, 1999.
PubMed
2) Weinfeld MS, et al : Aggravated renal dysfunction during intensive therapy for advanced heart failure. Arn Heart J 138 : 285-290, 1999.
 
3) Butler J, et al : Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 147 : 331-338, 2004.
PubMed
4) Gupta S, Neyses L : Diuretic usage in heart failure : a continuing conundrum in 2005. Eur Heart J 26 : 644-649, 2005.
PubMed
5) Fonarow GC : The Acute Decompensated Heart Failure National registry (ADHERE) : opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 4 (Suppl 7) : S21-30, 2003.
 
6) Yamamura Y, et al : OPC-41061, a highly potent human vasopressin V2-receptor antagonist : pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287 : 860-867, 1998.
PubMed
7) Hirano T, et al : Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 292 : 288-294, 2000.
PubMed
8) Miyazaki T, et al : Tolvaptan, an orally active vasopressin V2 receptor antagonist-pharmacology and clinical trials-. Cardiovasc Drug Rev (in press)
 
9) Onogawa T, et al : Effects of tolvaptan (OPC-41061), a vasopressin V2 receptor antagonist, and furosemide on hemodynamics, renal functions, serum electrolytes, and neurohormones in dogs with and without heart failure. Circulation 110 (Suppl III) 121, 2004.
 
10) Costello-Boerrigter LC, et al : Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 290 : F273-F278, 2006.
PubMed
11) Gheorghiade M, et al : Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure : results from a double-blind, randomized trial. Circulation 107 : 2690-2696, 2003.
PubMed
12) Gheorghiade M, et al : Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure : a randomized controlled trial. JAMA 291 (16) : 1963-1971, 2004.
PubMed
13) Gheorghiade M, et al : Rationale and design of the multicenter, randomized, double-blind, placebocontrolled study to evaluate the efficacy of vasopressin antagonism in heart failure : outcome study with tolvaptan (EVEREST). J Card Fail 11 (4) : 260-269, 2005.
 
14) Klein L, et al : Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure : results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 111 (19) : 2454-2460, 2005.
 
15) Gheorghiade M, et al : Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol 97 : 1064-1067, 2006.
PubMed
P.172 掲載の参考文献
1) Follath F, et al : Dose-ranging and safety wit intravenous levosimendan in low-output heart failure : experience in three pilot studies and outline of the levosimendan infusion vs Dobutamine (LIDO) Trial. Am J Cardiol 83 : 21-25, 1999.
 
2) Nanas JN, et al : Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Am J Cardiol 94 : 1329-1332, 2004.
PubMed
3) Parissis JT, et al : Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 93 : 1309-1312, 2004.
PubMed
4) Parissis JT, et al : Effects of levosimendan on markers of left ventricular diastolic function and neurohumoral activation in patients with advanced heart failure. Am J Cardiol 96 : 423-426, 2005.
 
5) Follath F, et al : Efficacy and safety of intaravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study) : a randomized double-blind trial. Lancet 360 : 196-202, 2002.
PubMed
6) Zaihs MN, et al : The effect of calcium sensitizer or an inotrope or none in chronic low output decompensated heart failure : results fron the Calcium Sensitizer or Inotrope or None in low Output Heart Failure Study (CASINO). (Abstract). J Am Coill Cardiol 43 (Suppl 1) : 206A-207A, 2004.
 
7) Delle Karth G, et al : Haemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Sacnd 47 : 1251-1256, 2003.
 
P.175 掲載の参考文献
1) Packer M, et al : Comparison of omapatrilat and enalapril in patients with chronic heart failure : the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Ciruculation 106 (8) : 920-926, 2002.
 
P.180 掲載の参考文献
1) Levine B, et al : Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 223 : 236-241, 1990.
 
2) Matsumori A, et al : Increased circulating cytokines in patients with cardiomyopathy and myocarditis. Br Heart J 72 : 561-566, 1994.
PubMed
3) Matsumori A : Cytokines in myocarditis and cardiomyopathies. Curr Opin Cardiol 11 : 302-309, 1996.
PubMed
4) Valgimigli M, et al : Tumor necrosis factor-α receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction. Circulation 111 : 863 -870, 2005.
 
5) Yamamoto K, et al : Attenuation of virus-induced myocardial injury by inhibition of the angiotensin II type 1 receptor signal and decreased nuclear factor-kappa B activation in knockout mice. J Am Coll Cardiol 42 : 2000-2006, 2003.
PubMed
6) Iwasaki A, et al : Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. J Am Coll Cardiol 33 : 1400-1407, 1999.
 
7) Trikas A, et al : Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. Eur J Heart Fail 8 : 804-809, 2006.
PubMed
8) Matsumori A, et al : Suppression of cytokines and nitric oxide and nitric oxide production, and protection against lethal endotoxemia and viral myocarditis by a new NF-κB inhibitor. Eur J Heart Fail 6 : 137-144, 2004.
 
9) Deswal A, et al : Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 99 : 3224-3226, 1999.
PubMed
10) Bozkurt B, et al : Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 103 : 1044-1047, 2001.
PubMed
11) Mann DL, et al : Effects of cytokine antagonism with etanercept on morbidity and mortality in patients with chronic heart failure : results of the RENAISSANCE, RECOVERY and RENEWAL trials. Paper presented at : Annual Meeting of the Heart Failure Society of America : September 25, 2002 ; Boca Raton, Fla.
 
12) Mann DL, et al : Targeted anticytokine therapy in patients with chronic heart failure : results of the Randomized Etanercept World Evalutation (RENEWAL). Circulation 109 : 1594-1602, 2004.
 
13) Packer M, et al : Randomized placebo-controlled dose-ranging trial of infliximab, a monoclonal antibody to tumor necrosis factor-α, in moderate to severe heart failure. Paper presented at : Annual Meeting of the Heart Failure Society of America ; September 25, 2002 ; Boca Raton, Fla.
 
14) Chung ES, et al ; Anti-TNF Therapy Against Congestive Heart Failure Investigators : Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure : results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 : 3133-3140, 2003.
PubMed
15) Suffredini AF, et al : Effects of recombinant dimeric TNF receptor on human inflammatory responses fbllowing intravenous endotoxin administration. J Immunol 155 : 5038-5045, 1995.
PubMed
P.186 掲載の参考文献
1) 駒村和雄 心疾患へのGH治療. ホルモンと臨床 48 : 387-392, 2000.
 
2) Fazio S, et al : A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 334 : 809-814, 1996.
 
3) Isgaard J, et al : A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J 19 : 1704-1711, 1998.
 
4) Osterziel KJ, et al : Randomized, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 351 : 1233-1237, 1998.
PubMed
5) 宮本哲也ほか : ミルリノン, hANP間欠投与中に成長ホルモンを追加投与して心機能改善を認めた拡張型心筋症の1例. 心臓 31 : 344-350, 1999.
Medical*Online
6) Al-Obaidi MK, et al : Plasma insulin-like growth factor-1 elevated in mild-to-moderate but not severe heart failure. Am Heart J 142 : E10, 2001.
 
7) Vaessen N, et al : A polymorphism in the gene for IGF-1 : functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 50 : 637-642, 2001.
PubMed
8) Vasan RS, et al : Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction : the Framingham Heart Study. Ann Intern Med 139 : 642-648, 2003.
PubMed
9) Bleumink GS, et al : Insulin-like growth factor-I gene polymorphism and risk of heart failure (the Rotterdam Study). Am J Cardiol 94 : 384-386, 2004.
PubMed
10) Barton PJ, et al : Myocardial insulin-like growth factor-I gene expression during recovery from heart failure after combined left ventricular assist device and clenbuterol therapy. Circulation 112 : 146-50, 2005.
 
11) Li RK, et al : Overexpression of transforming growth factor-betal and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation 96 : 874-881, 1997.
 
12) Delafontaine P, et al : Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 24 : 435-444, 2004.
PubMed
13) Donath MY, et al : Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure. J Clin Endocrinol Metab 83 : 3177-3183, 1998.
PubMed
14) Giustina A, et al : Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure. Am Heart J 137 : 1035-1043, 1999.
PubMed
15) Urbanek K, et al : Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ Res 97 : 663-673, 2005.
PubMed

XIV 機械的補助治療 ( 内科領域 )

P.193 掲載の参考文献
1) Spragg DD, et al : Regional alterations in protein expression in the dyssynchronous failing heart. Circulation 108 : 929-932, 2003.
PubMed
2) 松田直樹 : CRT概論. 両室ペースメーカー植え込み手技のTips & Trick (安藤献児編), 三輪書店, 2006.
 
3) Nelson GS, et al : Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation 102 : 3053-3059, 2000.
 
4) Yu CM, et al : Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Circulation 112 : 1580-1586, 2005.
 
5) Cleland JG, et al ; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators : The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 : 1539-1549, 2005.
 
6) de Sisti A, et al : Determinants of mortality in patients undergoing cardiac resynchronization therapy : baseline clinical, echocardiographic, and angioscintigraphic evaluation prior to resynchronization. Pacing Clin Electrophysiol 28 : 1260-1270, 2005.
PubMed
7) Lindenfeld J, et al : Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class rV heart failure. Circulation 115 : 204-212, 2007.
 
8) Bleeker GB, et al : Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. Circulation 113 : 969-976, 2006.
PubMed
9) White JA, et al : Delayed enhancement magnetic resonance imaging Predicts response to cardiac resynchronization therapy in patients with intraventricular dyssynchrony. J Am Coll Cardiol 48 : 1953-1960, 2006.
PubMed
10) Marcus GM, et al ; VENTAK CHF/CONTAK-CD Biventricular Pacing Study Investigators : Septal to posterior wall motion delay fails to predict reverse remodeling or clinical improvement in patients undergoing cardiac resynchronization therapy. J Am Coll Cardiol 46 : 2208-2214, 2005.
PubMed
11) Yu CM, et al : Benefits of cardiac resynchronization therapy for heart failure patients with narrow QRS complexes and coexisting systolic asynchrony by echocardiography. J Am Coll Cardiol 48 : 2251-2257, 2006.
PubMed
12) Bleeker GB, et al : Cardiac resynchronization therapy in patients with a narrow QRS complex. J Am Coll Cardiol 48 : 2243 -2250, 2006.
 
13) Abraham WT, et al ; Multicenter InSync ICD II Study Group : Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation 110 : 2864-2868, 2004.
 
14) Bristow MR, et al ; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators : Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 : 2140-2150, 2004.
 
15) Yu CM, et al : Intrathoracic impedance monitoring in patients with heart failure : correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation 112 : 841-848, 2005.
PubMed
P.198 掲載の参考文献
1) MERIT-HF study group : Effect of metoprolol CR/XL in chronic heart failure : Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 : 2001-2007, 1999.
 
2) Packer M, et al : Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 : 1651-1658, 2001.
PubMed
3) CIBIS-II investigators and committees : The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) : a randomised trial. Lancet 353 : 9-13, 1999.
 
4) Cohn JN, et al : A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 : 303-310, 1991.
PubMed
5) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study lnvestigators. N Engl J Med 341 : 709-717, 1999.
PubMed
6) Moss AJ, et al : Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 335 : 1933-1940, 1996.
 
7) Buxton AE, et al : A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 341 : 1882-1890, 1999.
 
8) Moss AJ, et al : Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 : 877-883, 2002.
PubMed
9) Bansch D, et al : Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy : the Cardiomyopathy Trial (CAT). Circulation 105 : 1453-1458, 2002.
PubMed
10) Strickberger SA, et al : Amiodarone versus implantable cardioverter-defibrillator : randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia (AMIOVIRT). J Am Coll Cardiol 41 : 1707-1712, 2003.
PubMed
11) Kadish A, et al : Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 : 2151-2158, 2004.
PubMed
12) Bardy GH, et al : Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 : 225-237, 2005.
 
13) The antiarrhythmics versus implantable defibrillators (AVID) investigators : A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337 : 1576-1583, 1997.
 
14) Kuck KH, et al : Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation 102 : 748-754, 2000.
PubMed
15) Connolly SJ, et al : Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 101 : 1297-1302, 2000.
PubMed
16) Cleland JGF, et al : The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 : 1539-1549, 2005.
PubMed
17) Bristow MR, et al : Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 : 2140-2150, 2004.
 
18) Carson P, et al : Mode of death in advanced heart failure : the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol 46 : 2329-2334, 2005.
 
19) Sanders GD, et al : Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 353 : 1471-1480, 2005.
PubMed
P.206 掲載の参考文献
1) Phillips SJ, et al : Percutaneous cardiopulmonary bypass : application and indication for use. Ann Thorac Surg 47 : 121-123, 1989.
PubMed
2) Takano T, et al : Clinical usefulness of intraaortic balloon pumping in acute myocardial infarction complicated with cardiogenic shock, ventricular septal perforation and mitral regurgitation. Jpn Circ J 48 : 678-689, 1984.
PubMed
3) 上村竜太, 高野照夫 : 知っておきたい補助循環IABP. Heart View 3 : 32-36, 1999.
 
4) Tanaka K, et al : Measurement of end-tidal carbon dioxide in patients with cardiogenic shock treated using a percutaneous cardiopulmonary assist system. J Nippon Med Sch 71 : 160-166, 2004.
PubMed
5) Ferguson JJ III, et al : The current practice of intra-aortic balloon counterpulsation : results from the Benchmark Registry. J Am Coll Cardiol 38 : 1456-1462, 2001.
 
6) Anderson RD, et al : Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock : Observations from the GUSTO-1 Study. J Am Coll Cardiol 30 : 708-715, 1997.
PubMed
7) Hochman JS, et al : Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 341 : 625-634, 1999.
PubMed
8) Barron HV, et al : The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction : Data from the National Registry of Myocardial Infarction 2. Am Heart J 141 : 933 -999, 2001.
 
9) Ohman EM, et al : Use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction. Results of a randomized trial. The Randomized IABP Study Group. Circulation 90 : 792-799, 1994.
 
10) Stone GW, et al : A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty. Second Primary Angioplasty in Myocardial Infraction (PAMI-II) Trial Investigators. J Am Coll Cardiol 29 : 1459-1467, 1997.
 
11) Chen EW, et al : Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. Circulation 108 : 951-957, 2003.
PubMed
12) Antman EM, et al : ACC/AHA guidelines for the management of patients With ST-elevation myocardial infarction : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110 : e82-292, 2004.
 
13) Hausmann J, et al : Prognosis after the implantation of an intra-aortic balloon pump in cardiac surgery calculated with a new score. Circulation 106 : 203-206, 2002.
 
14) Kato K, et al : Initial experiences of removal of intra-aortic balloon pumps with the Angio-Seal. J Invasive Cardio1 18 : 130-132, 2006.
 

XV 外科療法

P.215 掲載の参考文献
1) 松宮護郎, 松田暉 : 重症心不全における手術適応-左室形成術, 僧帽弁手術, 補助人工心臓の適応-. ICUとCCU 29 : 607-613, 2005.
 
2) Kazui T, et al ; Japanese Association for Thoracic Surgery Committee for Scienthic Affairs : Thoracic and cardiovascular surgery in Japan during 2004. Jpn J Thorac Cardiovasc Surg 54 : 363 -385, 2006.
 
3) Buckberg GD : Ventricular restoration-a surgical approach to reverse ventricular remodeling. Heart Fail Rev 9 : 233-239, 2004.
PubMed
4) Dor V : Reconstructive left ventricular surgery for post-ischemic akinetic dilatation. Semin Thorac Cardiovasc Surg 9 : 139-145, 1997.
PubMed
5) Menicanti L, DiDonato M : Surgical left ventricle reconstruction, pathophysiologic insights, results and expectation from the STICH trial. Eur J Cardiothorac Surg 26 (Suppl 1) : S42-46, 2004.
 
6) Romano MA, Bolling SF : Update on mitral repair in dilated cardiomyopathy. J Card Surg 19 : 396-400, 2004.
 
7) Fukamachi K, et al : Reduction of mitral regurgitation using the Coapsys device : a novel ex vivo method using excised recipients'hearts. ASAIO J 51 : 82-84, 2005.
PubMed
8) 松宮護郎 : 補助人工心臓-移植の代替になるか-. 今日の移植 18 : 302-308, 2005.
Medical*Online
9) Long JW, et al : Long-term destination therapy with HeartMate XVE left ventricular assist device : improved outcomes since the REMATCH study. Congest Heart Fail 11 : 133-138, 2005.
PubMed
10) Matsumiya G, et al : Who would be a candidate for bridge to recovery during prolonged mechanical left ventricular support in idiopathic dilated cardiomyopathy? J Thorac Cardiovasc Surg 130 : 699-704, 2005.
PubMed
11) Burkhoff D, et al : LVAD-induced reverse remodeling : basic and clinical implications for myocardial recovery. J Card Fail 12 : 227-239, 2006.
 
12) 福島教偉, 松田暉 : 心移植療法. Heart View 9 (2) : 134-140, 2005.
 
13) 中谷武嗣 : 日本における心臓移植の現況. 今日の移植 18 : 287-293, 2005.
Medical*Online
14) 白倉良太ほか : 心臓移植の課題. 今日の移植 18 : 325-327, 2005.
Medical*Online
15) 澤芳樹 : 重症心不全治療, 心筋再生療法の試み. Pharma Medica 22 : 59-63, 2004.
 
P.221 掲載の参考文献
1) 中谷武嗣 : 治療の進歩 ; 補助人工心臓. 日内会誌 94 : 111-118, 2005.
 
2) 中谷武嗣 : 心臓移植. 綜合臨牀 55 : 2053-2062, 2006.
Medical*Online
3) Rose EA, et al : Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 345 : 1435-1443, 2001.
PubMed
P.228 掲載の参考文献
1) Isomura T, et al : Left ventricle restoration in patients with non-ischemic dilated cardiomyopathy : risk factors and predictors of outcome and change of mid-term ventricular function. Eur J Cardiothorac Surg 19 : 684-689, 2001.
 
2) Matsui Y, et al : Integrated overlapping ventriculoplasty combined with papillary muscle placation for severely dilated heart failure. J Thorac Cardiovasc Surg 127 : 1221-1223, 2004.
 
3) Calafiore AM, et al : Septal reshaping for exclusion of anteroseptal dyskinetic or akinetic areas. Ann Thorac Surg 77 (6) : 2115-2121, 2004.
 
4) Athanasuleas CL, et al : Surgical ventricular restoration in the treatment of congestive heart failure due to post-infarction ventricular dilation. J Am Coll Cardiol 44 : 1439-1445, 2004.
PubMed
5) 加瀬川均 : 循環シミュレータを用いた僧帽弁形成術の医工学的検討-特に弁輪形成について-. 第18回関東心臓外科手術手技研究会 (平成18年11月8日, ホテルオークラ), 抄録, p2-9.
 
6) 今中和人ほか : 虚血性MRはmitral complexのみで決着がつくか? : 全周性弁輪縫縮+Alfieri法の検討. 第36回日本心臓血管外科学会 (平成18年4月14日, 盛岡). 日心外会誌 35 : 106 (抄録), 2006.
 
7) Acker MA, et al : Mitral valve surgery in heart failure : Results of the Acorn CorCapTM randomized trial. Program of 85th Annual Meeting of the American Association for Thoracic Surgery, p 64-65, 2005.
 
P.235 掲載の参考文献
1) Carpentier A, Chachques JC : Myocardial substitution with a stimulated skeletal muscle : first successful clinical case. Lancet 1 (8440) : 1267, 1985.
PubMed
2) Kass DA, et al : Reverse remodeling from cardiomyoplasty in human heart failure. External constraint versus active assist. Circulation 91 (9) : 2314-2318, 1995.
PubMed
3) Furnary AP, et al : Multicenter trial of dynamic cardiomyoplasty for chronic heart failure. The American Cardiomyoplasty Group. J Am Coll Cardiol 28 (5) : 1175-1180, 1996.
 
4) Carpentier A, et al : Dynamic cardiomyoplasty at seven years. J Thorac Cardiovasc Surg 106 (1) : 42-52 ; discussion 52-54, 1993.
PubMed
5) Furnary AP, et al : Long-term outcome, survival analysis, and risk stratification of dynamic cardiomyoplasty. J Thorac Cardiovasc Surg 112 (6) : 1640-1649 ; discusion 1649-1650, 1996.
 
6) Young J, Kirklin J : Cardiomyoplasty-skeletal muscle assist randomized trial (C-SMART) : 6 month results (abstract). Circulation 100 (suppl 1) : 1-514, 1999.
 
7) Salmons S : Cardiac assistance from skeletal muscle : should we be downhearted? Ann Thorac Surg 79 (4) : 1101-1103, 2005.
PubMed
8) Benicio A, et al : Reevaluation of long-term outcomes of dynamic cardiomyoplasty. Ann Thorac Surg 76 (3) : 821-827 ; discussion 827, 2003.
PubMed
9) Chachques JC, Carpentier A : Postoperative management. In : Cardiomyoplasty (ed by Carpentier A, et al), p 131-138, Futura, New York, 1991.
 
10) Jarvis JC, et al : Relationship between working capacity and activation frequency of chronically stimulated skeletal muscle. Proceedings of the World Symposium on Cardiomyoplasty, Biomechanical Assist and Artificial Heart, p 24 -26, 1993.
 
11) Grandjean P : Pulse generator system for dynamic cardiomyoplasty. In : Cardiomyoplasty (ed by Carpentier A, et al), p 123-130, Futura, New York, 1991.
 
12) el Oakley RM, Jarvis JC : Cardiomyoplasty. A critical review of experimental and clinical results. Circulation 90 (4) : 2085-2090, 1994.
PubMed
13) Shirota K, et al : Ventricular remodeling after cardiomyoplasty in heart failure sheep : passive and dynamic effects. Ann Thorac Surg 70 (6) : 2102-2106, 2000.
PubMed
14) Shirota K, et al : Functional recovery of the native heart after cardiomyoplasty in sheep with heart failure : passive and dynamic effects of volume loading. Ann Thorac Surg 73 (3) : 849-854, 2002.
PubMed
15) Acker MA, et al : Mitral valve surgery in heart failure : insights from the Acorn Clinical Trial. J Thorac Cardiovasc Surg 132 (3) : 568-577, 577 e 1-4, 2006.
 
P.241 掲載の参考文献
1) 日本胸部外科学会ホームページ : www.jpats.org
 
2) Tribouilloy CM, et al : Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation. Rationale for optimizing surgical indications. Circulation 99 : 400-405, 1999.
PubMed
3) Bonow RO, et al : ACC/AHA 2006 guidelines for the management of patients with valvular heart disease : a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 48 : el-148, 2006.
 
4) Shah AS, et al : Isolated mitral valve repair in patients with depressed left ventricular function. Ann Thorac Surg 80 : 1309-1314, 2005.
PubMed
5) Grossi EA, et al : Ischemic mitral valve reconstruction and replacement : Comparison of long-term survival and complications. J Thorac Cardiovasc Surg 122 : 1107-1124, 2001.
PubMed
6) Gillinov AM, et al : Is repair preferable to replacement for ischemic mitral regurgitation? J Thorac Cardiovasc Surg 122 : 1125-1141, 2001.
PubMed
7) Calafiore AM, et al : Mitral valve procedure in dilated cardiomyopathy : Repair or replacement. Ann Thorac Surg 71 : 1146-1153, 2001.
 
8) Spoor MT, et al : Flexible versus nonflexible mitral valve rings for congestive heart failure. Diffferential durability of repair. Circulation 114 (suppl I) : 1-67-71, 2006.
 
9) De Bonis M, et al : Mitral valve repair for functional mitral regurgitation in end-stage dilated cardiomyopathy. Role of the "Edge-to-edge" technique. Circulation 112 (Suppl I) : 1-402-408, 2005.
 
10) Kincaid EH, et al : Anterior leaflet augmentation for ischemic mitral regurgitation. Ann Thorac Surg 78 : 564-568, 2004.
PubMed
11) Dobre M, et al : Anatomic and physiologic correction of the restricted posterior mitral leaflet motion in chronic ischemic mitral regurgitation. J Thorac Cardiovasc Surg 120 : 409-411, 2000.
PubMed
12) Messas E, et al : Efficacy of chordal cutting to relieve chronic persistent ischemic mitral regurgitation. Circulation 108 (suppl II) : II-111-115, 2003.
 
13) Yamamoto H, et al : Effectively treating ischemic mitral regurgitation with chordal cutting in combination with ring annuloplasty and left ventricular reshaping approach. J Thorac Cardiovasc Surg 130 : 589-590, 2005.
PubMed
14) Messas E, et al : Chordal cutting does not adversely aiifect left ventricle contractile function. Circulation 114 (suppl I) : 1-524-528, 2006.
 
15) Kron IL, et al : Surgical relocation of the posterior papillary muscle in chronic ischemic mitral regurgitation. Ann Thorac Surg 74 : 600-601, 2002.
PubMed
16) Hvass U, et al : Papillary muscle sling : a new functional approach to mitral repair in patients with ischemic left ventricular dysfunction and functional mitral regurgitation. Ann Thorac Surg 75 : 809-811, 2003.
PubMed
17) Nair RU, et al : Left ventricular volume reduction without ventriculectomy. Ann Thorac Surg 71 : 2046-2049, 2001.
PubMed
18) Matsui Y, et al : Integrated overlapping ventriculoplasty combined with papillary muscle plication for severely dilated heart failure. J Thorac Cardiovasc Surg 127 : 1221-1223, 2004.
PubMed
19) Fukamachi K, et al : Off-pump mitral valve repair using the Coapsys device : apilot study in a pacing-induced mitral regurgitation model. Ann Thorac Surg 77 : 688-692, 2004.
 
20) Mishra YK, et al : Coapsys mitral annuloplasty for chronic functional ischemic mitral regurgitation : 1-year results. Ann Thorac Surg 81 : 42-46, 2006.
PubMed
P.248 掲載の参考文献
1) Barnard CN : A human cardiac transplant : an interim report of a successful operation performed at Groote Schuur Hospital, Cape town. S Afr Med J 41 : 1271-1274, 1967.
 
2) Fukushima N, et al : Early result of heart transplantation in Japan : Osaka University experience. Asian Cardiovasc Thorac Ann 12 : 154-158, 2004.
PubMed
3) Hertz MI, et al : Scientific Registry of the lnternational Society for Heart and Lung Transplantation : introduction to the 2005 annual reports. J Heart Lung Transplant 24 : 939-944, 2005.
 

XVI 血液浄化療法

P.254 掲載の参考文献
1) 公文啓二 : ECUM. 重症心不全診断・治療・病理の最前線 (北村惣一郎ほか編), p 199-202, 医学書院, 2003.
 
2) 公文啓二 : 血液浄化, 除水はいつ, どのようにするか. 心不全を癒す (吉川純一, 松崎益徳編), p146-149, 文光堂, 1998.
 
3) 公文啓二 : 人工心肺使用時の血液浄化. 腎と透析 48 : 680-684, 2000.
 
4) 公文啓二 : 急性腎不全の治療. 集中治療 10 (臨) : e68-e74, 1998.
 
5) 木全直樹 : 血液透析・血液濾過・血液濾過透析の原理・臨床. Clinical Engineering 17 : 442-446, 2006.
 
6) 平澤博之 : hemofilterおよびその寿命と交換のタイミング. CHDFの理論と実際-原理・施行法編- (平澤博之編), p39-46, 総合医学社, 1998. '
 
7) 大石義英 : 急性血液浄化療法専用装置・システムの変遷と最近の動向. Clinical Engeneering 17 : 951-957, 2006.
 
8) Haruna M, et al : Effect of atrial natriuretic peptide (ANP) on blood volume and hepatic blood flow in oliguric patients after cardiovascular surgery. Anesthesiology 85 : A96, 1996.
 
9) 公文啓二 : 急性腎不全. 標準集中治療医学 (天羽敬祐編), p158-162, 真興交易, 2000.
 
10) Varriale P, Mossavi A : The benefit of low-dose dopamine during vigorous diuresis for congestive heart failure associated with renal insufficiency : does it protect renal function? Clin Cardiol 20 : 627-630, 1997.
PubMed
P.258 掲載の参考文献
1) Cody RJ, et al : Diuretic treatment for the sodium retention of congestive heart failure. Arch Intern Med 154 : 1905-1914, 1994.
PubMed
2) Wilkins MR, et al : Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of Guanosine 3', 5'-cyclic monophosphate degradation. J Clin Invest 85 : 1274-1279, 1990.
PubMed
3) Marenzi S, et al : Interrelation of humoral factors, hemodynamics, and fluid and salt metabolism in congestive heart failure : effects of extracorporeal ultrafiltration. Am J Med 94 : 49-56, 1993.
 
4) Agostoni P, et al : Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency : failure of furosemide to provide the same result. Am J Med 96 : 191-199, 1994.
PubMed
5) Grootendorst A, et al : High-volume hemofiltration improves hemodynamics of endotoxin-induced shock in the pig. J Crit Care 7 : 67-75, 1992.
 
6) Stein B, et al : Influence of continuous haemofiltration on hemodynamics and central blood volume in experimental endotoxic shock. Intensive Care Med 16 : 494-499, 1990.
PubMed
P.262 掲載の参考文献
1) Kramer P, et al : Arteriovenous hemofiltration. A new and simple method for treatment of overhydrated patients resistant to diuretics. Klin Wochenschr 55 : 1121-1122, 1977.
PubMed
2) 坂口俊文 : 持続的血液浄化の歴史・原理・臨床. Clinical Engineering 17 : 448-454, 2006.
 
3) 川西秀樹 : CHDF. HDF療法ハンドブック (日本HDF研究会編), p 186-202, 南江堂, 2000.
 
4) 武本佳昭ほか : 持続的血液濾過と持続的血液濾過透析. 日本臨牀 62 (増刊号5) : 249-252, 2004.
Medical*Online
5) (社) 日本透析医学会 : 慢性血液透析用バスキュラーアクセスの作製および修復に関するガイドライン. 透析会誌 38 : 1491-1551, 2005.
 
6) 三瀬直文ほか : メシル酸ナファモスタットによる重篤な薬剤アレルギーの検討. 透析会誌 37 : 65-70, 2004.
 
7) 片山浩 : クリアランスからみた持続血液浄化法の比較. 日集中治会誌 5 : 115-121, 1998.
 
8) Hirasawa H, et al : Endotoxin adsorption or hemodiafiltration in the treatment of multiple organ failure. Curr Opin Crit Care 6 : 421-425, 2000.
 
9) Oda S, et al : Continuous hemofiltration/hemodiafiltration in critical care. Ther Apher 6 : 193-198, 2002.
PubMed
10) 仲村将高ほか : 体外循環時の生体反応-免疫防御機構. 日本臨牀 62 (増刊号5) : 50-54, 2004.
Medical*Online
11) 中敏夫ほか : CHF/CHDFによる炎症性サイトカインの除去. 救急・集中治療 18 : 97-103, 2006.
 

XVII 輸液療法

P.270 掲載の参考文献
1) 磯部光章 : 心不全患者への輸液. 心不全治療 (矢崎義雄監), p403-411, メディカルレビュー社, 1997.
 
2) Cleland JGF, et al : The EuroHeart Failure survey programme-a survey on the quaUty of care among patients with heart failure in Europe. Part 1 : patient characteristics and diagnosis. Eur Heart J 24 : 442-463, 2003.
PubMed
3) Forrester JS, et al : Correlative classification of clinical and hemodynamic function after acute myocardial infarction. Am J Cardiol 39 : 137, 1977.
PubMed

XVIII 温熱療法

P.278 掲載の参考文献
1) Tei C, et al : Acute hemodynamic improvement by thermal vasodilation in congestive heart failure. Circulation 91 : 2582-2590, 1995.
PubMed
2) Tei C, Tanaka N : Thermal vasodilation as a treatment of congestive heart failure : a novel approach. J Cardiol 27 : 29-30, 1996.
PubMed
3) Kihara T, et al : Repeated sauna treatment improves vascular endothelial and cardiac function in patients with chronic heart failure. J Am Coll Cardiol 39 : 754-759, 2002.
PubMed
4) Drexler H, Hornig B : Endothelial dysfunction in human disease. J Mol Cell Cardiol 31 : 51-60, 1999.
 
5) Katz SD : Mechanisms and implications of endothelial dysfunction in congestive heart failure. Curr Opin Cardiol 12 : 259-264, 1997.
PubMed
6) Smith CJ, et al : Reduced gene expression of vascular endothelial NO synthase and cyclooxygenaselin heart failure. Circ Res 78 : 58-64, 1996.
PubMed
7) Agnoletti L, et al : Serum from patients with severe heart failure downregulates eNOS and is proapoptotic : role of tumor necrosis factor-alpha. Circulation 100 : 1983-1991, 1999.
PubMed
8) Ikeda Y, et al : Repeated sauna therapy increases arterial endothelial nitric oxide synthase expression and nitric oxide production in cardiomyopathic hamsters. Circ J 69 : 722-729, 2005.
PubMed
9) Ikeda Y, et al : Effect of repeated sauna therapy on survival in TO-2 cardiomyopathic hamsters with heart failure. Am J Cardiol 90 : 343-345, 2002.
 
10) Imamura M, et al : Repeated thermal therapy improves impaired vascular endothelial function in patients with coronary risk factors. J Am Coll Cardiol 38 : 1083-1088, 2001.
PubMed
11) Eichhorn EJ : Prognosis determination in heart failure. Am J Med 110 : 14S-36S, 2001.
PubMed
12) Tsutamoto T, et al : Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure : prognostic role of plasma brain natriuretic peptide concenfration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96 : 509-516, 1997.
PubMed
13) Cohn JN : Abnormalities of peripheral sympathetic nervous system control in congestive heart failure. Circulation 82 : 159-67, 1990.
 
14) Nolan J, et al : Prospective study of heart rate variability and mortality in chronic heart failure : results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 98 : 1510-1516, 1998.
PubMed
15) Kihara T, et al : Effects of repeated sauna treatment on ventricular arrhythmias in patients with chronic heart failure. Circ J 68 : 1146-1151, 2004.
PubMed

XIX 運動療法

P.290 掲載の参考文献
1) Hunt SA : ACC/AHA Guideline update for the diagnosis and management of chronic heart failure in the adult. J Am Coll Cardiol 46 : 1-82, 2005.
 
2) Itoh H, et al : Effects of enoximone on exercise tolerance in patients with mild to moderate heart failure. Am J Cardiol 68 : 360-364, 1991.
PubMed
3) Maskin CS, et al : Failure of dobutamine to increase exercise capacity despite hemodynamic improvement in severe chronic heart failure. Am J Cardiol 51 : 177-182, 1983.
PubMed
4) Tanabe Y, et al : Acute effect of percutaneous transvenous mitral commissurotomy on ventilatory and hemodynamic responses to exercise. Pathophysiological basis for early symptomatic improvement. Circulation 88 : 1770-1778, 1993.
PubMed
5) Conn EH, et al : Exercise responses before and after physical conditioning in patients with severely depressed left ventricular function. Am J Cardiol 49 : 296-300, 1982.
PubMed
6) Itoh H, Kato K : Exercise training after cardiac surgery. In : Exercise Gas Exchange in Heart Disease (ed by Wasserman K), p 229-244, Futura, New York, 1996.
 
7) Belardinelli R, et al : Effects of moderate exercise training on thallium uptake and contractile response to low-dose dobutamine of dysfunctional myocardium in patients with ischemic cardiomyopathy. Circulation 97 : 553-561, 1998.
PubMed
8) Belardinelli R, et al : Effects of exercise training on left ventricular filling at rest and during exercise in patients with ischemic cardiomyopathy and severe left ventricular systolic dysfunction. Am Heart J 32 : 61-70, 1996.
 
9) Adamopoulos S, et al : Physical training improves skeletal muscle metabolism in patients with chronic heart failure. J Am Coll Cardiol 21 : 1101-1106, 1993.
PubMed
10) Akashi Y, et al : Short-term physical training improves vasodilatory capacity in cardia patients. Jpn Heart J 43 : 13-24, 2002.
 
11) Coats AJS, et al : Controlled trial of physical training in chronic heart failure. Circulation 85 : 2119-2131, 1992.
 
12) 小林敏生 : 運動療法は呼吸機能を改善するか. 循環器NOW 10, 運動指導・運動療法 (村山正博編), p87-89, 南江堂, 1995.
 
13) Belardinelli R, et al : Randomized, controlled trial of long-term moderate exercise training in chronic heart failure : effects on functional capacity, quality of life, and clinical outcome. Circulation 99 : 1173-1182, 1999.
PubMed
14) ExTraMATCH Collaborative : Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 328 : 189-191, 2004.
PubMed
15) Giannuzi P, et al : Recommendations for exercise training in chronic heart failure patients. Working group on cardiac rehabilitation & exercise physiology and working group on heart failure of the European Society of Cardiology. Eur Heart J 22 : 125-135, 2001.
 
16) 伊東春樹 : Anaerobic threshold (AT). 循環器負荷試験法 (水野康ほか編), p 256-294, 診断と治療社, 1991.
 
17) Koike A, et al : Detecting abnormalities in left ventricular function during exercise by respiratory measurement. Circulation 80 : 1737-1746, 1989.
PubMed

XX 予後

P.299 掲載の参考文献
1) Levy D, et al : Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347 : 1397-1402, 2002.
PubMed
2) Fonarow GC, et al : Risk stratification for in-hospital mortality in acutely decompensated heart failure. Classification and regression tree analysis. JAMA 293 : 572-580, 2005.
PubMed
3) Tsuchihashi M, et al : Clinical characteristics and prognosis of hospitalized patients with congestive heart failure-A study in Fukuoka, Japan. Jpn Circ J 64 : 953-959, 2000.
PubMed
4) Stevenson LW, et al : Target heart failure populations for new therapies. Circulation 92 : 174-181, 1995.
 
5) Lee DS, et al : Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 294 : 1240-1247, 2005.
PubMed
6) Simon T, et al : Sex differences in the prognosis of congestive heart failure. Results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation 103 : 375-380, 2001.
PubMed
7) Aurigemma GP, Gaasch WH : Diastolic heart failure. N Engl J Med 351 : 1097-1105, 2004.
PubMed
8) Bhatia RS, et al : Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355 : 260-269, 2006.
 
9) Zile MR, Brutsaert DL : New concepts in diastolic dysfunction and diastolic heart failure : Part I : Diagnosis, prognosis, and measurements of diastolic function. Circulation 105 : 1387-1393, 2002.
PubMed
10) Xie G, et al : Prognostic value of doppler transmitral flow patterns in patients with congestive heart failure. J Am Coll Cardiol 24 : 132-139, 1994.
PubMed
11) Hillege HL, et al : Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102 : 203-210, 2000.
PubMed
12) Hillege HL, et al : Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113 : 671-678, 2006.
 
13) Tsutamoto T, et al : Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol 47 : 582-586, 2006.
PubMed
14) Phillips CO, et al : Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure, A Meta-analysis. JAMA 291 : 1358-1367, 2004.
PubMed
15) Fox E, et al : Evaluation of prognostic criteria for determining hospice eligibility in patients with advanced lung, heart, or liver disease. JAMA 291 : 1358-1367, 2004.
PubMed
P.303 掲載の参考文献
1) Eichhorn EJ, Bristow MR : Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circualtion 94 : 2285-2296, 1996.
 
2) Eichhorn EJ : Prognosis determination in heart failure. Am J Med 110 (7A) : 14S-36S, 2001.
 
3) Iwanaga Y, et al : B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure : comparison between systolic and diastolic heart failure. J Am Coll Cardiol 47 : 742-748, 2006.
PubMed
4) Gosling O, et al : Angiotensin II, but not aldosterone and rennin, correlates positively with increased concentrations of N-terminal pro-brain natriuretic peptide in patients with chronic heart failure. Heart 91 : 1223-1224, 2005.
PubMed
5) Tsutamoto T, et al : Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 20 : 1799-1807, 1999.
PubMed
6) Tsutamoto T, et al : Attenuation of compensation of endogeneous cardiac natriuretic peptide system in chronic heart failure : prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96 : 509-516, 1997.
PubMed
7) McDonagh TA, et al : Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 86 : 21-26, 2001.
 
8) Wallen T, et al : Brain natriuretic peptide predicts mortality in the elderly. Heart 77 : 264-267, 1997.
PubMed
9) Maisel A, et al : Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 44 : 1328-1333, 2004.
PubMed
10) Richards AM, et al : B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 107 : 2786-2792, 2003.
PubMed
11) Richards M, et al ; Christchurch Cardioendocrine Research Group ; Australia-New Zealand Heart Failure Group : Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol 47 : 52-60, 2006.
 
12) Kazanegra R, et al : A rapid test for B-type natriuretic peptide correrates with falling wedge pressures in patients treated for decompensated heart failure : a pilot study. J Card Fail 7 : 21-29, 2001.
PubMed
13) Cheng V, et al : Arapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure : a pilot study. J Am Coll Cardiol 37 : 386-391, 2001.
 
14) Cohn JN, Tognoni G ; for Val-HeFT Investigators : A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 : 1667-1675, 2001.
 
15) Latini R, et al ; for the Val-HeFT Investigators : The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 25 : 292-299, 2004.
PubMed
16) Troughton RW, et al : Treatment in heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 : 1126-1130, 2000.
PubMed
17) Jourdain P, et al : Benefit of BNP plasma levels for optimizing therapy : the systolic heart failure treatment supported by BNP multicenter randomized trial (STARS-BNP) [abstract] . J Am Coll Cardiol 45 : 3A, 2005.
 
18) Berger R, et al : B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105 : 2392-2397, 2002.
 
19) Klingenberg R, et al : Elevated B-type natriuretic peptide is associated with ventricular tachyarrythmia events determined by ICD interrogation in congestive heart failure patients [Abstract]. J Am Coll Cardiol 45 : 110A, 2005.
 

XXI 危険因子・予防

P.310 掲載の参考文献
1) American Heart Association : Heart Disease and Stroke Statistics-2005 Update. TX ; American Heart Association, Dallas, 2005.
 
2) Tsuchihashi M, et al : Clinical characteristics and prognosis of hospitalized patients with congestive heart failure-a study in Fukuoka, Japan. Jpn Circ J 64 : 953-959, 2000.
PubMed
3) Kannel WB, Belanger AJ : Epidemiology of heart failure. Am Heart J 121 : 951-957, 1991.
PubMed
4) Tresch DD, McGough MF : Heart failure with normal systolic function : acommon disorder in older people. J Am Geriatr Soc 43 : 1035-1042, 1995.
 
5) Kannel WB, et al : Role of diabetes in congestive heart failure : the Framingham study. Am J Cardiol 34 : 29-34, 1974.
PubMed
6) Shindler DM, et al : Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 77 : 1017-1020, 1996.
PubMed
7) Iribarren C, et al : Glycemic control and heart failure among adult patients with diabetes. Circulation 103 : 2668-2673, 2001.
PubMed
8) Kostis JB, et al ; SHEP Cooperative Research Group : Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 278 : 212-216, 1997.
 
9) Kenchaiah S, et al : Obesity and the risk of heart failure. N Engl J Med 347 : 305-313, 2002.
PubMed
10) Kistorp C, et al : Plasma adiponectin, body mass index, and mortality in patients With chronic heart failure. Circulation 112 : 1756-1762, 2005.
PubMed
11) He J, et al : Risk factors for congestive heart failure in US men and women : NHANES I epidemiologic follow-up study. Arch Intern Med 161 : 996-1002, 2001.
PubMed
12) Abramson JL, et al : Moderate alcohol consumption and risk of heart failure among older persons. JAMA. 285 : 1971-1977, 2001.
PubMed
13) Burke A, Fitzgerald GA : Oxidative stress and smoking-induced vascular injury. Prog Cardiovasc Dis 46 : 79-90, 2003.
PubMed
14) Kannel WB, et al : Changing epidemiological features of cardiac failure. Br Heart J 72 : S3-S9, 1994.
PubMed
15) Schillaci G, et al : High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension. J Hypertens 19 : 2265-2270, 2001.
 
16) Horio T, et al : Influence of low high-density lipoprotein cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension. Am J Hypertens 16 : 938-944, 2003.
PubMed
17) Jullien V, et al : Relationship between left ventricular mass and serum cholesterol level in the untreated hypertensive. J Hypertens 16 : 1043-1047, 1998.
PubMed
18) Matsumori A ; Assessment of Response to Candesartan in Heart Failure in Japan (ARCH-J) Study Investigators : Efficacy and saiety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail 5 : 669-677, 2003.
 
19) Hori M, et al ; MUCHA Investigators : Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure : the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 147 : 324-330, 2004.
PubMed
20) Effect of metoprolol CR/XL in chronic heart failure : Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 : 2001-2007, 1999.
PubMed
21) Pfeffer MA, et al ; CHARM Investigators and Committees : Effects of candesartan on mortality and morbidity in patients with chronic heart failure : the CHARM-Overall programme. Lancet 362 : 759-766, 2003.
PubMed
P.315 掲載の参考文献
1) Hunt SA, et al : ACC/AHA Practice Guidelines-Full Text. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult, A Report of ACC/AHA Task on Practice Guidelines ACC-www. acc. org, AHA-www.americanheart.org, p 1-83, 2005.
 
2) American Heart Association : Heart Disease and Stroke Statistics : 2005 Update, American Heart Association, Dallas, 2005.
PubMed
3) Shenoy M, et al : Diagnosis and management of stage A heart failure. Congest Heart Fail 12 : 146-152, 2006.
 
4) He J, et al : Risk factors for congestive heart failure in US men and women : NHANES I epidemiologic follow-up study. Arch Intern Med 161 : 996-1002, 2001.
PubMed
5) 山崎力, 百村伸一 : 心不全の病態と診断-1, 心不全の概念と疫学. 日本医師会インターネット生涯教育講座 <心不全の診療>, 2006. 9.
 
6) 五十嵐美穂子ほか : うっ血性心不全患者における心電図QRS幅の検討 : 両室ペーシングの一指標. J Cardiol 40 : 103-109, 2001.
 
7) Levy D, et al : The progression form hypertension to congestive heart failure. JAMA 275 : 1557-1562, 1996.
 
8) VA Cooperative Study Group : Anti-hypertensive agents. JAMA 213 : 1143-1152, 1970.
 
9) Staessen JA, et al : Cardiovascular protection and blood pressure reduction : a meta-analysis. Lancet 358 : 1305-1315, 2001.
PubMed
10) Psaty BM, et al : Health outcomes associated With various antihypertensive therapies used as firstline agents : a network meta-analysis. JAMA 289 : 2534-2544, 2003.
PubMed
11) ALLHAT Collaborative Research Group : Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone : the Antihypertensive and Lipid-lowering treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 283 : 1967-1975, 2000.
 
12) 今井潤 : 国民栄養調査. Mebio 19 : 127-136, 2002.
 
13) Vaur L, et al : Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria : observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study. Diabetes Care 26 : 855-860, 2003.
PubMed
14) 半田俊之介 : 喫煙が循環系に及ぼす影響について. 循環器専門医 13 : 333-338, 2005.
 
15) Vasan RS, et al : Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction : the Framingham Heart Study. Circulation 107 : 1486-1491, 2003.
PubMed
P.319 掲載の参考文献
1) Tan C, et al : Daunomycin, an antitumor antibiotics, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer 20 : 333-353, 1967.
PubMed
2) Lefrak EA, et al : The cardiotoxicity of adriamycin and daunomycin in children. Cancer 32 : 302-314, 1973.
 
3) Praga C, et al : Adriamycin cardiotoxicity : asurvey of 1273 patients. Cancer Treat Rep 63 : 827-834, 1979.
 
4) Lenaz L, et al : Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev 3 : 111-120, 1976.
PubMed
5) Bristow MR, et al : Doxorubicin cardiomyopathy : evaluation by phonocardiography, endomyocardial biopsy, and cardiac catherization. Ann Intern Med 88 : 168-175, 1978.
 
6) Von Hoff DD, et al : Risk factors for doxorubicin-induced congestive heart failure. Ann Intem Med 91 : 710-717, 1979.
 
7) Minow RA, et al : Adriamycin cardiomyopathy risk factors. Cancer 39 : 1397-1402, 1977.
PubMed
8) 岡田義信ほか : 心エコー図によるdoxorubicinの心毒性およびその適正な投与方法の検討. 癌と化学療法 24 (14) : 2137-2141, 1997.
Medical*Online
9) 大熊攻ほか : Adriamycin心毒性に関する臨床研究-全国実態調査の集計成績-. 癌と化学療法 8 (4) : 596-602, 1981.
 
10) Posner LE, et al : Mitoxantrone : an overview of safety and toxicity. Invest New Drugs 3 : 123-132, 1985.
PubMed
11) Gottdiener JS, et al : Cardiotoxicity with high-dose cyclophosphamide therapy. Arch Intern Med 141 : 758-763, 1981.
PubMed
12) Clavel M, et al : 5-Fluorouracil (5-FU) cardiotoxicity : 33 events out of 1145 consecutive patients. Proc Am Soc Clin Oncol 10 : 346, 1991.
 
13) Branwald E : Heart Disease 7th Heart Disease A textbook of Cardiovasucular Medicine, p 2122-2125, Elsevier Saunders, 2005.
 
14) 西條長宏, 山本昇 : 心毒性. がん化学療法の副作用と対策, p 122-216, 中外医学社, 1998.
 

XXII 管理・看護

P.327 掲載の参考文献
1) Hunt SA, et al : ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) : developed in collaboration with the American College of Chest Physicians and the lnternational Society for Heart and Lung Transplantation : endorsed by the Heart Rhythm Society. Circulation 112 : e154-235, 2005.
 
2) Swedberg K, et al : [Diagnosis and treatment of chronic heart disease. Guidelines of the European Society of Cardiology. Revision 2005]. Kardiol Pol 63 : 509-543 ; discussion 544-548, 2005.
 
3) 松崎益徳ほか : 慢性心不全治療ガイドライン (2005年改訂版). Jpn Circ J 65 : 841-861, 2005.
 
4) Heart Failure Society Of America : HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 12 : e1-2, 2006.
PubMed
5) Springer J, et al : Prognosis and therapy approaches of cardiac cachexia. Curr Opin Cardiol 21 : 229-233, 2006.
PubMed
6) Sasayama S, et al : Effects of nocturnal oxygen therapy on outcome measures in patients with chronic heart failure and cheyne-stokes respiration. Circ J 70 : 1-7, 2006.
PubMed
7) Davis MM, et al ; American Heart Association ; American College of Cardiology : Influenza vaccination as secondary prevention for cardiovascular disease : ascience adVisory from the American Heart Association/American College of Cardiology. Circulation 114 : 1549-1553, 2006.
 
8) Gurfinkel EP, et al : Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. Eur Heart J 25 : 25-31, 2004.
PubMed
9) Gohler A, et al : A systematic meta-analysis of the efficacy and heterogeneity of disease management programs in congestive heart failure. J Card Fail 12 : 554-567, 2006.
PubMed
10) Yu DS, et al : Disease management programmes for older people with heart failure : crucial characteristics which improve post-discharge outcomes. Eur Heart J 27 : 596-612, 2006.
PubMed
11) Hauptman PJ : Palliation in heart failure : when less and more are more. Am J Hosp Palliat Care 23 : 150-152, 2006.
 
12) Zick SM, et al : The prevalence and pattern of complementary and alternative supplement use in individuals with chronic heart failure. J Card Fail 11 : 586-589, 2005.
PubMed
13) American Heart Association Nutrition Committee ; Lichtenstein AH, et al : Diet and lifestyle recommendations revision 2006 : a scientific statement from the American Heart Association Nutrition Committee. Circulation 114 : 82-96, 2006.
PubMed
14) Middlekauff HR : Acupuncture in the treatment of heart failure. Cardiol Rev 12 : 171-173, 2004.
PubMed
15) 加藤祐子ほか : 心不全患者の家庭管理. medicina 41 : 1849-1853, 2004.
 
P.332 掲載の参考文献
1) 松崎益徳ほか : 慢性心不全治療ガイドライン (2005年改訂版). http://www.j-circ.or.jp, p 1-67, 2005.
 
2) The Criteria Committee of the New York Heart Association : Nomenclature and Criteria for Diagnosis, 9th ed, Little Brown, 1994.
 
3) Goldman L, et al : Comparative reproducibility and validity of systems for assessing cardiovascular functional class : advantages of a new specific activity scale. Circulation 64 : 1227-1234, 1981.
PubMed
4) 篠山重威 : 重症度. 現代医療 22 : 555-560, 1990.
 
5) Hillege HL, et al ; Candesartan in Heart Failure : Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators : Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113 : 671-678, 2006.
 
6) Maeda K, et al : Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135 : 825-832, 1998.
PubMed
7) Tsutsui H, et al : Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol 88 : 530-533, 2001.
PubMed
8) Andersen P, Henriksson J : Capillary supply of the quadriceps femoris muscle of man : adaptive response to exercise. J Physiol 270 : 677-690, 1977.
PubMed
9) Clausen Jp : Effect of physical training on cardiovascular adjustments to exercise in man, Physiol Rev 57 : 779-815, 1977.
PubMed
P.338 掲載の参考文献
1) 佐藤志樹ほか : 心不全患者における呼吸管理の実際. 現代医療 27 : 2399-2402, 1995.
 
2) Hanly PJ, Zuberi-Khokhar NS : Increased mortality associated with Cheyne-Stokes respiration in patients with congestive heart failure. Am J Respir Crit Care Med 153 : 272-276, 1996.
PubMed
3) Nohria A, et al : Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 41 : 1797-1804, 2003.
PubMed
4) Harrison A, et al : B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 39 : 131-138, 2002.
 
5) Bersten AD, et al : Treatment of severe cardiogenic pulmonary edema with continuous positive airway pressure delivered by face mask. N Engl J Med 325 : 1825-1830, 1991.
 
6) Lin M, et al : Reappraisal of continuous positive airway pressure therapy in acute cardiogenic pulmonary edema. Short-term results and long-term follow-up. Chest 107 : 1379-1386, 1995.
PubMed
7) Mehta S, et al : Randomized, prospective trial of bilevel versus continuous positive airway pressure in acute pulmonary edema. Crit Care Med 25 : 620-628, 1997.
PubMed
8) Masip J, et al : Noninvasive pressure support ventilation versus conventional oxygen therapy in acute cardiogenic pulmonary oedema : A randomised trial. Lancet 356 : 2126-2132, 2000.
PubMed
9) Park M, et al : Randomized, prospective trial of oxygen, continuous positive airway pressure, and bilevel positive airway pressure by face mask in acute cardiogenic pulmonary edema. Crit Care Med 32 : 2407-2415, 2004.
PubMed
10) Blackshear JL, et al : Nocturnal dyspnea and atrial fibrillation predict Cheyne-Stokes respirations in patients with congestive heart failure. Arch Intern Med 155 : 1297-1302, 1995.
PubMed
11) Javaheri S, et al : Sleep apnea in 81 ambulatory male patients with stable heart failure : types and their prevalences, consequences and presentations. Circulation 97 : 2154-2159, 1998.
PubMed
12) Javaheri S, et al : Effects of nasal O2 on sleep-related disordered breathing in ambulatory patients with stable heart failure. Sleep 22 : 1101-1106, 1999.
PubMed
13) Andreas S, et al : Nasal oxygen and muscle sympathetic nerve activity in heart failure. Chest 123 : 366-371, 2003.
PubMed
14) Takasaki Y, et al : Effect of nasal continuous positive airway pressure on sleep apnea in congestive heart failure. Am Rev Respir Dis 140 : 1578-1584, 1989.
PubMed
15) Bradley TD, et al : CANPAP Investigators. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 353 : 2025-2033, 2005.
PubMed
P.342 掲載の参考文献
1) Sandham JD, et al : A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 348 : 5-14, 2003.
PubMed
2) Cahalan MK, et al : American Society of Echocardiography and Society of Cardiovascular Anesthesiologists task force guidelines for training in perioperative echocardiography. Anesth Analg 94 : 1384-1388, 2002.
PubMed
3) Eagle KA, et al : ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery-Executive summary : A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Am Call Cardiol 39 (3) : 542-553, 2002.
 
4) Auerbach AD, Goldman L : Beta-blockers and reduction of cardiac events in noncardiac surgery : Scientific review. JAMA 287 : 1435-1444, 2002.
PubMed
5) Pronovost PJ, et al : Physician staffing patterns and clinical outcomes in critically ill patients : A systematic review. JAMA 288 : 2151 -2162, 2002.
 
6) Kehlet H, Holte K : Effect of postoperative analgesia on surgical outcome. Br J Anaesth 87 : 62-72, 2001.
PubMed
P.347 掲載の参考文献
1) Rochat RW, et al ; the Maternal Mortality Collaborative : Maternal mortality in the United States : report from the Maternal Mortality Collaborative. Obstet Gynecol 72 : 91-97, 1988.
PubMed
2) Siu SC, Colman JM : Heart disease and pregnancy. Heart 85 : 710-715, 2001.
PubMed
3) Clark SL, et al : Critical care obstetrics, 2nd ed, Blackwell, Boston, 1991.
 
4) Abbas AE, et al : Pregnancy and the cardiovascular system. Int J Cardiol 98 : 179-189, 2005.
PubMed
5) Whittemore R, et al : Pregnancy and its outcome in women with and without surgical treatment of congenital heart disease. Am J Cardiol 50 : 641-651, 1982.
PubMed
6) Siu SC, et al : Risk and predictors for pregnancy-related complications in women with heart disease. Circulation 96 : 2789-2794, 1997.
PubMed
7) Weiss BM, et al : Outcome of cardiovascular surgery and pregnancy : a systematic review of the period 1984-1996. Am J Obstet Gynecol 179 : 1643-1653, 1998.
PubMed
8) 中澤誠ほか : 我が国における新生児心疾患の発生状況 (厚生省心身障害研究, 心疾患研究班研究報告より). 日児誌 90 : 2578-2587, 1986.
 
9) Romano-Zelekha O, et al : The risk for congenital heart defects in offspring of individuals with congenital heart defects. Clin Genet 59 : 325-329, 2001.
PubMed
10) Burn J, et al : Recurrence risks in offspring of adults with major heart defects : results from first cohort of British collaborative study. Lancet 351 : 311-316, 1998.
PubMed
11) Ayhan A, et al : Pregnancy and its complications after cardiac valve replacement. Int J Gynaecol Obstet 35 : 117-122, 1991.
PubMed
12) Presbitero P, et al : Pregnancy in cyanotic congenital heart disease. Outcome of mother and fetus. Circulation 89 : 2673-2676, 1994.
PubMed
13) Monnery L, et al : Primary pulmonary hypertension in pregnancy ; a role for novel vasodilators. Br J Anaesth 87 : 295-298, 2001.
PubMed
14) Dajani AS, et al : Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA 277 : 1794-1801, 1997.
PubMed
15) 宮武邦夫ほか : 感染性心内膜炎の予防と治療に関するガイドライン. Circ J 67 (Suppl IV) : 1039-1110, 2003.
 
P.352 掲載の参考文献
1) 村上美好ほか : 呼吸理学療法. 写真でわかる臨床看護技術, p104-113, インターメディカ, 2005.
 
2) 1998-1999年度合同研究班報告 : 慢性心不全の治療ガイドライン. Japanese Circulation Journal 64 (Suppl IV) : 1042-1044, 2000.
 
3) 心臓血管研究所付属病院栄養部 : 心臓病防ぐ食事・治す食事, p44-47, 新興医学出版, 2000.
 
4) 永井良三ほか : 管理・処置・治療. 循環器研修医ノート (永井良三ほか編), p309-311, 診断と治療社, 2003.
 
5) 和泉徹ほか : 慢性心不全患者の家庭管理. 入退院を繰り返す慢性心不全の臨床 (和泉徹ほか編), p175-183, 医学書院, 2002.
 
6) 佐々木達哉 : 心不全とつきあうコツ, p8, フジメディカル出版, 1999.
 
P.355 掲載の参考文献
1) 福原俊一 : アウトカム研究における健康関連QOLの測定. 呼吸と循環 49 : 1147-1155, 2001.
 
2) 福原俊一ほか : SF-36v2(TM)日本語版マニュアル, 健康医療評価研究機構, 2004.
 
3) Johansson P, et al : Factors and interventions influencing health-related quality of life in patients with heart failure : a review of the literature. Eur J Cardiovasc Nurs 5 : 5-15, 2006.
PubMed
4) Hobbs FD, et al : Impact of heart failure and left ventricular systolic dysfunction on quality of life. A cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J 23 : 1867-1876, 2002.
 
5) Kitzman DW, et al : Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 288 : 2144-2150, 2002.
PubMed
6) Juenger J, et al : Health related quality of life in patients with congestive heart failure : comparison with other chronic diseases and relation to functional variables. Heart 87 : 235-241, 2002.
PubMed
7) Riedinger MS, et al : Quality of life in patients with heart failure : do gender differences exist? Heart Lung 30 : 105-116, 2001.
PubMed
8) Riedinger MS, et al : Quality of life in women with heart failure, normative groups, and patients with other chronic conditions. Am J Crit Care 11 : 211-219, 2002.
PubMed
9) Okura Y, et al : Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 57 : 1096-1103, 2004.
 
10) Swenson JR, Clinch JJ : Assessment of quality of 1ife in patients with cardiac disease : the role of psychosomatic medicine. J Psychosom Res 48 : 405-415, 2000.
 
11) Alonso J, et al : Health-related quality of life associated with chronic conditions in eight countries : results from the International Quality of Life Assessment (IQOLA) Project. Qual Life Res 13 : 283-298, 2004.
PubMed
12) Davies M, et al : Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study : a population based study. Lancet 358 : 439-444, 2001.
PubMed
13) Mitani H, et al : Health-related quality of life of Japanese patients with chronic heart failure : assessment using the Medical Outcome Study Short Form 36. Circ J 67 : 215-220, 2003.
PubMed
14) 大野有希子ほか : 心臓の拡張機i能障害患者のhealth related quahty of life (新潟・佐渡心不全研究). 呼吸と循環 54 : 1019-1026, 2006.
 
15) Okura Y, et al : Burden of cardiac dysfunction on the community (Niigata-Sado Heart Failure Study). J Card Fail 12 : S155, 2006.
 

XXIII 心不全での合併症 - 成因・病態・治療 -

P.362 掲載の参考文献
1) Feinberg WM, et al : Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 155 : 469-473, 1995.
PubMed
2) Benjamin EJ, et al : Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271 : 840-844, 1994.
 
3) Dries DL, et al : Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with a symptomatic and symptomatic left ventricular systolic dysfunction : a retrospective analysis of the SOLVD trials. J Am Coll Cardiol 32 : 695-703, 1998.
PubMed
4) CONSENSUS Trial Study Group : Effects of enalapril on mortality in severe congestive heart failure : results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 : 1429-1435, 1987.
 
5) Shiroshita-Takeshita A, et al : Atrial fibrillation : Basic mechanisms, remodeling and triggers. J Interv Card Electrophysiol 13 : 181-193, 2005.
PubMed
6) Li D, et al : Promotion of atrial fibrillation by heart failure in dogs : atrial remodeling of a different sort. Circulation 100 : 87-95, 1999.
PubMed
7) Demellis J, et al : Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 25 : 1100-1107, 2004.
PubMed
8) Goette A, et al : Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 35 : 1669-1677, 2000.
PubMed
9) Kumagai K, et al : The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 62 : 105-111, 2004.
 
10) 1999-2000年度合同研究班報告 : 心房細動治療 (薬物) ガイドライン. Japanese Circulation Journal 65 (Suppl V) : 931-978, 2001.
 
11) Wyse D G, et al : A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 : 1825-1833, 2002.
PubMed
12) Van Gelder IC, et al : A comparison of rate control and rhythm control in patients with recurrent atrial fibrillation. N Engl J Med 347 : 1834-1840, 2002.
PubMed
13) Carlsson J, et al : Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation : the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 41 : 1690-1696, 2003.
PubMed
14) Hohnloser SH, et al : Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF) : a randomised trial. Lancet 356 : 1789-1794, 2000.
 
15) Yamashita T, et al : Investigation of the optimal treatment strategy for atrial fibrillation in Japan. Circ J 67 : 738-741, 2003.
PubMed
P.368 掲載の参考文献
1) Adamson PB, Gilbert EM : Reducing the risk of sudden death in heart failure with β-blockers. J Cardiac Fail 12 : 734-746, 2006.
 
2) Beuckelmann DJ, et al : Alterations of K+currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ Res 73 : 379-385, 1993.
PubMed
3) Li GR, et al : Transmural action potential and ionic current remodeling in ventricles of failing canine hearts. Am J Physiol 283 : H1031-1041, 2002.
 
4) Piacentino V 3rd, et al : Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ Res 92 : 651-658, 2003.
PubMed
5) Bers DM : Cardiac excitation-contraction coupling. Nature 415 : 198-205, 2002.
PubMed
6) Kamkin A, et al : Stretch-activated currents in ventricular myocytes : amplitude and arrhythmogenic effects increase with hypertrophy. Cardiovasc Res 48 : 409-420, 2000.
PubMed
7) Domanski MJ, et al : Effect of angiotensin converting enzyme inhibiton on sudden death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 33 : 598-604, 1999.
 
8) Connolly SJ, et al ; on behalf of the investigators of the AVID, CASH and CIDS studies : Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J 21 : 2071-2078, 2000.
 
9) Moss AJ, et al : Improved survival with an implantable defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 335 : 1933-1940, 1996.
 
10) Buxton AE, et al ; for the Multicenter Unsustained Tachycardia Trial Investigators : A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 341 : 1882-1890, 1999.
 
11) Moss AJ, et al ; for the Multicenter Automatic Defibrillator Implantation Trial II Investigators : Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 : 877-883, 2002.
PubMed
12) Bardy GH, et al ; for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators : Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 : 225-237, 2005.
 
13) Grimm W, et al : Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy : results of the Marburg Cardiomyopathy Study. Circulation 108 : 2883-2891, 2003.
PubMed
14) Kadish A, et al ; for the Defibrillators in Non-lschemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators : Prophylactic defibrillator implantation in patients with nonsustained dilated cardiomyopathy. N Engl J Med 350 : 2151-2158, 2004.
 
15) Strickberger SA, et al ; for the AMIOVIRT Investigators : Amiodarone versus implantable cardioverter-defibrillator : Randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol 41 : 1707-1712, 2003.
PubMed
P.374 掲載の参考文献
1) Francis GS : Development of arrhythmias in the patient with congestive heart failure : pathophysiology, prevalence and prognosis. Am J Cardiol 57 : 3B-7B, 1986.
PubMed
2) Nakamura K, et al : Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 105 : 2867-2871, 2002.
PubMed
3) Juurlink DN, et al : Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 : 543-551, 2004.
PubMed
4) Effect of metoprolol CR/XL in chronic heart failure : Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 : 2001-2007, 1999.
PubMed
5) Roden DM, Viswanathan PC : Genetics of acquired long QT syndrome. J Clin Invest 115 : 2025-2032, 2005.
PubMed
6) Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure : meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 350 : 1417-1424, 1997.
PubMed
7) Bardy GH, et al ; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators : Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 : 225-237, 2005.
 
8) Yano M, et al : FKBP12. 6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation 107 : 477-484, 2003.
PubMed
9) Nakamura K, et al : Relationship between oxidative stress and systolic dysfunction in patients with hypertrophic cardiomyopathy. J Card Fail 11 : 117-123, 2005.
PubMed
10) Bhatnagar A : Electrophysiological effects of 4-hydroxynonenal, an aldehydic product of lipid peroxidation, on isolated rat ventricular myocytes. Circ Res 76 : 293-304, 1995.
PubMed
P.381 掲載の参考文献
1) Zannad F, et al : Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes : The EFICA study. Eur J Heart Fail 8 : 697-705, 2006.
PubMed
2) Hunt SA, et al : ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 (6) : el-82, 2005.
 
3) Hochman JS, et al : One-year survival following early revascularization for cardiogenic shock. JAMA 285 : 190-192, 2001.
PubMed
4) Barron HV, et al : The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction : data from the National Registry of Myocardial Infarction 2. Am Heart J 141 : 933-939, 2001.
 
5) Cotter G, et al : L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 101 : 1358-1361, 2000.
 
6) Cotter G, et al : LINCS : L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock : a prospective randomized study. Eur Heart J 24 : 1287-1295, 2003.
PubMed
7) Kohsaka S, et al : Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med 165 : 1643-1650, 2005.
PubMed
8) Abraham E, et al : Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353 : 1332-1341, 2005.
 
9) Cooper HA, et al : Diuretics and risk of arrhythmic death in patients With left ventricular dysfunction. Circulation 100 : 1311-1315, 1999.
PubMed
10) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
 
11) Pitt B, et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003.
PubMed
12) Bauersachs J, et al : Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction : role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 39 : 351-358, 2002.
PubMed
13) Taylor AL, et al : Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 : 2049-2057, 2004.
PubMed
14) Packer M, et al : Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100 : 2312-2318, 1999.
 
15) Massie BM, et al : Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure : results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch Intern Med 161 : 165-171, 2001.
PubMed
16) Cohn JN, Tognoni G : A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 : 1667-1675, 2001.
PubMed
17) McMurray JJ, et al : Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin-converting-enzyme inhibitors : the CHARM-Added trial. Lancet 362 : 767-771, 2003.
PubMed
18) Pfeffer MA, et al : Effects of candesartan on mortality and morbidity in patients with chronic heart failure : the CHARM-Overall programme. Lancet 362 : 759-766, 2003.
PubMed
19) Packer M, et al : The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 334 : 1349-1355, 1996.
 
20) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) : a randomised trial. Lancet 353 : 9-13, 1999.
 
21) Effect of metoprolol CR/XL in chronic heart failure : Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 : 2001-2007, 1999.
PubMed
22) Packer M, et al : Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 : 1651-1658, 2001.
PubMed
23) Krum H, et al : Effects of initiating carvedilol in patients with severe chronic heart failure : results from the COPERNICUS Study. JAMA 289 : 712-718, 2003.
PubMed
24) Witherow FN, et al : Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation 104 : 2177-2181, 2001.
 
25) Cruden NL, et al : Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Arterioscler Thromb Vasc Biol 24 : 1043-1048, 2004.
 
26) Yalcin AU, et al : Effect of sertraline hydrochloride on cardiac autonomic dysfunction in patients with hemodialysis-induced hypotension. Nephron Physiol 93 : 21-28, 2003.
 
P.387 掲載の参考文献
1) Simonneau G, et al : Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 : 5S-12S, 2004.
PubMed
2) McLaughlin W, McGoon MD : Pulmonary arterial hypertension. Circulation 114 : 1417-1431, 2006.
 
3) Lane KB, et al ; The International PPH Consortium : Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. Nat Genet 26 : 81-84, 2000.
 
4) Kidd L, et al : Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation 87 : 138-151, 1993.
 
5) Colle IO, et al : Diagnosis of portopulmonary hypertension in candidates for liver transplantation : a prospective study. Hepatology 37 : 401-409, 2003.
PubMed
6) Opravil M, et al : HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 155 : 990-995, 1997.
 
7) Atwood CW Jr, et al : Pulmonary artery hypertension and sleep-disordered breathing : ACCP evidence-based clinical practice guidelines. Chest 126 : 72S-77S, 2004.
PubMed
8) Riedel M, et al : Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 81 : 151-158, 1982.
PubMed
9) 吉川純一 : 循環器フィジカル・イグザミネーションの実際, 文光堂, 2005.
 
10) Currie PJ, et al : Continuous wave Doppler determination of right ventricular pressure : a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 6 : 750-756, 1985.
PubMed
11) Weiss BM, et al : Outcome of pulmonary vascular disease in pregnancy : a systematic overview from 1978 through 1996. J Am Coll Cardiol 31 : 1650-1657, 1998.
PubMed
12) 中野赳ほか : 循環器病の診断と治療に関するガイドライン. 肺高血圧症治療ガイドライン. Jpn Circ J 65 : 1077-1118, 2001.
 
13) Galie N, et al ; Task Force : Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25 : 2243-2278, 2004.
 
P.391 掲載の参考文献
1) Yamamoto K, et al : Left ventricular function and coagulation activity in healed myocardial infarction. Am J Cardiol 81 : 920-923, 1998.
PubMed
2) Pulerwitz T, et al : A rationale for the use of anticoagulation in heart failure management. J Thromb Thrombolysis 17 : 87-93, 2004.
PubMed
3) 峰松一夫 : 心原性脳塞栓症の現状. 脳と循環 3 : 29-33, 1998.
 
4) Yamaguchi T : Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke 31 : 817-821, 2000.
 
5) Cleland JG, et al : Is aspirin safe for patients with heart failure? Br Heart J 74 : 215-219, 1995.
PubMed
6) No authors : Cardiogenic brain embolism. Cerebral Embolism Task Force. Arch Neurol 43 : 71-84, 1986.
 
7) Roberts WC, et al : Idiopathic dilated cardiomyopathy : analysis of 152 necropsy patients. Am J Cardiol 60 : 1340-1355, 1987.
PubMed
8) Rubenstein JJ, et al : Clinical spectrum of the sick sinus syndrome. Circulation 46 : 5-13, 1972.
PubMed
9) Fairfax AJ, et al : Systemic embolism in chronic sinoatrial disorder. N Engl J Med 295 : 190-192, 1976.
PubMed
10) Gotoh F, Tanaka K : Regulation of cerebral blood flow. In : Handbook of Clinical Neurology (ed by Vinken PJ, et al), p 47-77, Elsevier, Amsterdam, 1988.
 
11) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 臓器障害を合併する高血圧. 高血圧治療ガイドライン, p35-46, 2004.
 
12) Lee CW, et al : Cerebral metabolic abnormalities in congestive heart failure detected by proton magnetic resonance spectroscopy. J Am Coll Cardiol 33 : 1196-1202, 1999.
PubMed
13) 星本正姫ほか : 心疾患患者における運動時の脳の酸素状態に関する研究. 日本臨床生理学会雑誌 34 : 199-205, 2004.
 
14) 荒尾正人ほか : ピモベンダンが心機能および脳血流に及ぼす影響の検討-心プール・脳血流シンチグラフィを用いて-. 心臓 37 : 374-380, 2005.
Medical*Online
P.396 掲載の参考文献
1) Tsutsui H, et al : Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol 88 : 530-533, 2001.
PubMed
2) McAlister EA, et al : Renal insufficiency and heart failure : Prognostic and therapeutic implications from a prospective cohort study. Circulation 109 : 1004-1009, 2004.
 
3) Hillege HL, et al : Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102 : 203-210, 2000.
PubMed
4) Silverberg D, et al : The cardio-renal anemia syndrome : does it exist? Nephrol Dial Transplant 18 (Suppl 8) : viii7-12, 2003.
 
5) Anand IS, et al : Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure : results from Val-HeFT. Circulation 112 : 1121-1127, 2005.
PubMed
P.400 掲載の参考文献
1) Naschitz JE, et al : Heart diseases affecting the liver and liver diseases affecting the heart. Am Heart J 140 (1) : 111-120, 2000.
PubMed
2) Wanless IR, et al : Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). Hepatology 21 (5) : 1232-1237, 1995.
PubMed
3) Hoeper MM, et al : Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 363 (9419) : 1461-1468, 2004.
PubMed
4) Liu H, et al : Cardiac and vascular changes in cirrhosis : pathogenic mechanisms. World J Gastroenterol 12 (6) : 837-842, 2006.
PubMed
P.404 掲載の参考文献
1) Hunter J : Original cases, Library of Royal College Surgeon of England, 1781.
 
2) Cheyne J : A case of apoplexy in which the fleshly part of the heart was converted into fat. Dublin Hospital Reports 2 : 216-223, 1818.
 
3) Stokes W : The Disease of the Heart and Aorta, p 320-327, Hodges & Smith, Dublin, 1854.
 
4) Franklin KA, et al : Hemodynamics, cerebral circulation, and oxygen saturation in Cheyne-Stokes respiration. J Appl Physiol 83 : 1184-1191, 1997.
PubMed
5) Fukui S, et al : Central sleep apnea predicts the prognosis of patients with chronic heart failure independent of brain-natriuretic peptide. Circ J 69 (suppl I) : 412, 2005.
 
6) Shinozaki T, et al : Nocturnal oxygen therapy decreases brain BNP in chronic heart failure patients with central sleep apnea. Circulation 110 (Suppl III) : III-366, 2004.
 
7) Pembrey MS : Observations on Cheyne-Stokes respiration. J Pathol Bacteriol 12 : 259-266, 1908.
 
8) Hanley PF, et al : The effect of oxygen on respiration and sleep in patients with congestive heart failure. Ann Int Med 111 : 777-782, 1989.
 
9) Andreas S, et al : Improvement of exercise capacity with treatment of Cheyne-Stokes respiration in patients with chronic heart failure. J Am Coll Cardiol 27 : 1486-1490, 1996.
 
10) Staniforth AD, et al : Effect of oxygen on sleep quality, cognitive function and sympathetic activity in patients with chronic heart failure and Cheyne-Stokes respiration. Eur Heart J 19 : 922-928, 1998.
 
11) Sasayama S, et al : Effects of nocturnal oxygen therapy on outcome measures in patients with chronic heart failure and Cheyne-Stokes respiration. Circ J 70 : 1-7, 2006.
PubMed
12) Javaheri S : A mechanism of central sleep apnea in patients with heart failure, N Engl J Med 3451 : 949-954, 1999.
 
13) Nakayama H, et al : Effect of ventilatory drive on carbon dioxide sensitivity below eupnea during sleep. Am Respir Crit Care Med 165 : 1251-1259, 2002.
PubMed
14) Andreas S, et al : Noctumal oxygen and hypercapnic ventilatory response in patients with congestive heart failure. Resp Med 92 : 426-431, 1998.
 
15) Bradley TD, et al : Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 353 : 2025-2033, 2005.
PubMed
P.410 掲載の参考文献
1) Somers VK, et al : Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 96 : 1897-1904, 1995.
PubMed
2) Narkiewicz K, et al : Nocturnal continuous positive airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea. Circulation 100 : 2332-2335, 1999.
PubMed
3) Narkiewicz K, et al : Altered cardiovascular variability in obstructive sleep apnea. Circulation 98 : 1071-1077, 1998.
PubMed
4) Imadojemu VA, et al : Impaired vasodilator responses in obstructive sleep apnea are improved with continuous positive airway pressure therapy. Am J Respir Crit Care Med 165 : 950-953, 2002.
PubMed
5) Kaneko Y, et al : Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med 348 : 1233-1241, 2003,
PubMed
6) Kasai T, et al : 第69回日本循環器学会2005にて発表.
 
7) Mansfield DR, et al : Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir Crit Care Med 169 : 361-366, 2004.
PubMed
8) Naughton MT, et al : Etifect of continuous positive airway pressure on intrathoracic and left ventricular transmural pressures in patients with congestive heart failure. Circulation 91 : 1725-1731, 1995.
PubMed
9) Bradley TD, et al : Cardiac output response to continuous positive airway pressure in congestive heart failure. Am Rev Respir Dis 145 : 377-382, 1992.
PubMed
10) Tkacova R, et al : Effect of continuous positive airway pressure on mitral regurgitant fraction and atrial natriuretic peptide in patients with heart failure. J Am Coll Cardiol 30 : 739-745, 1997.
PubMed
11) Javaheri S : Effects of continuous positive airway pressure on sleep apnea and ventricular irritability in patients with heart failure. Circulation 101 : 392-397, 2000.
PubMed
12) Naughton MT, et al : Effects of nasal CPAP on sympathetic activity in patients with heart failure and central sleep apnea. Am J Respir Crit Care Med 152 : 473-479, 1995.
PubMed
13) Sin DD, et al : Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. Circulation 102 : 61-66, 2000.
PubMed
14) Bradley TD, et al : Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 353 : 2025-2033, 2005.
PubMed
15) Dohi T, et al : 2004 AHAにて発表,
 
16) Kasai T, et al : Efficacy of nasal bi-level positive airway pressure in congestive heart failure patients with Cheyne-Stokes respiration and central sleep apnea. Circ J 69 : 913-921, 2005.
PubMed
17) Dohi T, et al : 第69回日本循環器学会2005にて発表.
 
18) Teschler H, et al : Adaptive pressure support servo-ventilation : a novel treatment for Cheyne-Stokes respiration in heart failure. Am J Respir Crit Care Med 164 : 614-619, 2001.
PubMed
19) Kasai T, et al : First experience of using new adaptive servo-ventilation device for Cheyne-Stokes respiration with central sleep apnea among Japanese patients with congestive heart failure : report of 4 clinical cases. Circ J 70 : 1148-1154, 2006.
PubMed

XXIV 心不全の原因疾患 ( 基礎疾患 ) 別の臨床的事項 - 病態, 発症機序 ( 心不全 ) , 治療 -

P.420 掲載の参考文献
1) Pfeffer MA, et al : Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 : 669-677, 1992.
 
2) The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators : Effect on ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342 : 821-828, 1993.
 
3) Pitt B, et al : Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure : randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355 : 1582-1587, 2000.
PubMed
4) Dickstein K, et al ; OPTIMAAL Steering Committee of the OPTIMAAL Study Group : Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction : the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360 : 752-760, 2002.
 
5) Pfeffer MA, et al ; Valsartan in Acute Myocardial Infarction Trial Investigators : Valsartan, Captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 : 1893-1906, 2003.
 
6) Cleland JG, et al ; Carvedilol hibemating reversible ischaemia trial : marker of success investigators : Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial) : randmised controlled trial. Lancet 362 : 14-21, 2003,
PubMed
7) Hori M, et al ; MUCHA Investigators : Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanease patients with chronic heart failure : the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 147 : 324-330, 2004.
 
8) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
 
9) Dor V, et al : Efficacy of endoventricular patch plasty in large postinfarction akinetic scar and severe left ventricular dysfunction : Comparison with a series of large dyskinetic scars. J Thorac Cardiovasc Surg 116 : 50-59, 1998.
PubMed
10) Moss AJ, et al ; Multicenter Automatic Defibrillator Implantation Trial Investigators : Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 335 : 1933-1940, 1996.
PubMed
11) Buxton AE, et al ; Multicenter Unsustained Tachycardia Trial Investigators : A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 341 : 1882-1890, 1999.
 
12) Moss AJ, et al ; Multicenter Automatic Defibrillator lmplantation Trial II lnvestigators : Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 : 877-883, 2002.
 
13) Cleland J, et al ; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators : The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 : 1539-1549, 2005.
 
P.424 掲載の参考文献
1) Fuster V, et al : The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 47 : 525-531, 1981.
PubMed
2) Ogasawara S, et al : Prognosis of dilated cardiomyopathy : from a retrospective to a prospective study employing multivariate analysis. Jpn Circ J 51 : 699-706, 1987.
PubMed
3) Matsumura Y, et al : Long-term prognosis of dilated cardiomyopathy revisited : an improvement in survival over the past 20 years. Circ J 70 : 376-383, 2006.
PubMed
4) Inoue S, et al : Effect of beta-blocker therapy on severe ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy. Jpn Circ J 64 : 87-92, 2000.
 
P.428 掲載の参考文献
1) Maron BJ, et al ; Task Force on Clinical Expert Consensus Documents. American College of Cardiology ; Committee for Practice Guidelines. European Society of Cardiology : American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42 : 1687-1713, 2003.
 
2) Spirito P, Autore C : Management of hypertrophic cardiomyopathy. BMJ 332 : 1251-1255, 2006.
PubMed
3) Nishimura RA, Holmes DR Jr : Clinical practice. Hypertrophic obstructive cardiomyopathy. N Engl J Med 350 : 1320-1327, 2004.
PubMed
4) Ikeda H, et al : Predictors of death from congestive heart failure in hypertrophic cardiomyopathy. Am J Cardiol 83 : 1280-1283, A1289, 1999.
 
5) Hiasa G, et al : Cardiac sympathetic nerve activity can detect congestive heart failure sensitively in patients with hypertrophic cardiomyopathy. Chest l26 : 679-686, 2004.
 
6) Maron MS, et al : Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348 : 295-303, 2003.
PubMed
7) Olivotto I, et al : Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J Am Coll Cardiol 47 : 1043-1048, 2006.
 
8) Olivotto I, et al : Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 104 : 2517-2524, 2001.
PubMed
9) Harris KM, et al : Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 114 : 216-225, 2006.
PubMed
10) Maron MS, et al : Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outnow tract obstruction. Circulation 114 : 2232-2239, 2006.
 
11) Maron BJ, et al : The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 44 : 2044-2053, 2004.
PubMed
12) Araujo AQ, et al : Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am J Cardiol 96 : 1563-1567, 2005.
PubMed
13) van der Lee C, et al : Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets. Circulation 112 : 482-488, 2005.
PubMed
P.436 掲載の参考文献
1) Richardson P, et al : Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task force on the Definition and Classfication of cardiomyopathies. Circulation 93 : 841-842, 1996.
 
2) 河合祥雄 : "拘束型心筋症" と特発性拘束型心筋症. 別冊医学のあゆみ循環器疾患 (矢崎義雄編), p663-666, 医歯薬出版, 2001.
 
3) Mogensen J, et al : Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J Clin Invest 111 : 209-216, 2003.
PubMed
4) Kokado H, et al : Clinical features of hypertrophic cardiomyopathy caused by a Lys183 deletion mutation in the cardiac troponin I gene. Circulation 102 : 663-669, 2000.
PubMed
5) Fujino N, et al : A novel mutation Lys273Glu in the cardiac troponin T gene shows high degree of penetrance and transition from hypertrophic to dilated cardiomyopathy. Am J Cardiol 89 : 29-33, 2002.
PubMed
6) Konno T, et al : A novel missense mutation in the myosin binding protein-C gene is responsible for hypertrophic cardiomyopathy with left ventricular dysfunction and dilation in elderly patients. J Am Coll Cardio1 41 : 781-786, 2003.
 
7) Konno T, et al : A novel mutation in the cardiac myosin-binding protein C gene is responsible for hypertrophic cardiomyopathy with severe ventricular hypertrophy and sudden death. Clin Sci (Lond) 110 : 125-131, 2006.
PubMed
8) Konno T, et al : Phenotypic differences between electrocardiographic and echocardiographic determination of hypertrophic cardiomyopathy in genetically affected subjects. J Intern Med 258 : 216-224, 2005.
PubMed
9) Murphy RT, et al : Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy. Lancet 363 : 371-372, 2004.
PubMed
10) Gomes AV, et al : Mutations in human cardiac troponin I that are associated with restrictive cardiomyopathy affect basal ATPase activity and the calcium sensitivity of force development. J Biol Chem 280 : 30909-30915, 2005.
PubMed
11) Yumoto F, et al : Drastic Ca2+ sensitization of myofilament associated with a small structural change in troponin I in inherited restrictive cardiomyopathy. Biochem Biophys Res Commun 338 : 1519-1526, 2005.
PubMed
12) Konno T, et al : Genotype-phenotype variations in cardiomyopathies caused by a cardiac Troponin Igene mutation. Circulation : abstract, 2006.
 
13) 中谷敏 : 拘束型心筋症. 綜合臨牀 50 : 1597-1602, 2001.
 
14) 坂田泰史, 山本一博 : 収縮性心膜炎と拘束型心筋症をいかに鑑別するか. 心エコー 7 : 384-391, 2006.
Medical*Online
15) Hatle LK, et al : Differentiation of constrictive pericarditis and restrictive cardiomyopathy by Doppler echocardiography. Circulation 79 : 357-370, 1989.
PubMed
16) Ha JW, et al : Differentiation of constrictive pericarditis from restrictive cardiomyopathy using mitral annular velocity by tissue Doppler echocardiography. Am J Cardiol 94 : 316-319, 2004.
PubMed
17) 日本循環器学会 : 循環器病の診断と治療に関するガイドライン (2004年度合同研究班報告) 慢性心不全治療ガイドライン, 2005年改訂版.
 
P.445 掲載の参考文献
1) Fenelon G, et al : Tachycardiomyopathy : mechanisms and clinical implications. Pacing Clin Electrophysiol 19 : 95-106, 1996.
 
2) Maron BJ, et al : Contemporary definitions and classification of the cardiomyopathies : an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee ; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups ; and Council on Epidemiology and Prevention. Circulation 113 : 1807-1816, 2006.
PubMed
3) Moe GW, Armstrong P : Pacing-induced heart failure : amodel to study the mechanism of disease progression and novel therapy in heart failure. Cardiovasc Res 42 : 591-599, 1999.
 
4) Khasnis A, et al : Tachycardia-induced cardiomyopathy : a review of literature. Pacing Clin Electrophysiol 28 : 710-721, 2005.
PubMed
5) Perreault CL, et al : Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing-induced heart failure. J Clin Invest 89 : 932-938, 1992.
PubMed
6) Kiuchi K, et al : Myocardial beta-adrenergic receptor function during the development of pacing-induced heart failure. J Clin Invest 91 : 907-914, 1993.
PubMed
7) Ishikawa Y, et al : Downregulation of adenylylcyclase types V and VI mRNA levels in pacing-induced heart failure in dogs. J Clin Invest 93 : 2224-2229, 1994.
 
8) Spinale FG, et al : Changes in myocardial blood flow during development of and recovery from tachycardia-induced cardiomyopathy. Circulation 85 : 717-729, 1992.
PubMed
9) Shannon RP, et al : Impaired regional subendocardial coronary flow reserve in conscious dogs with pacing-induced heart failure. Am J Physiol 265 : H801-809, 1993.
PubMed
10) Komamura K, et al : Exhaustion of Frank-Starling mechanism in conscious dogs with heart failure. Am J Physiol 265 : H1119-1131, 1993.
PubMed
11) Komamura K, et al : Alterations in left ventricular diastolic function in conscious dogs with pacing-induced heart failure. J Clin Invest 89 : 1825-1838, 1992.
PubMed
12) Spinale FG, et al : Cellular and extracellular remodeling with the development and recovery from tachycardia-induced cardiomyopathy : changes in fibrillar collagen, myocyte adhesion capacity and proteoglycans. J Mol Cell Cardiol 28 : 1591-1608, 1996.
PubMed
13) Shannon RP, et al : Alterations in myocardial contractility in conscious dogs with dilated cardiomyopathy. Am J Physiol 260 (6 Pt 2) : H1903-1911, 1991.
 
14) Qin F, et al : Selegiline attenuates cardiac oxidative stress and apoptosis in heart failure : association with improvement of cardiac function. Eur J Pharmacol 461 : 149-158, 2003.
PubMed
15) Sen L, et al : Differences in mechanisms of SR dysfunction in ischemic vs. idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 279 : H709-718, 2000.
PubMed
P.449 掲載の参考文献
1) 岩井和郎ほか : 剖検例からみたサルコイドーシスの日米比較-心サルコイドーシスを中心にして-, 厚生省特定疾患びまん性肺疾患調査研究班平成4年度報告書, p35-37, 1993.
 
2) 寺崎文生, 北浦泰 : 拡張型心筋症を呈する心臓サルコイドーシス-左室縮小形成術 (バチスタ手術) 症例を中心に-. サルコイドーシス/肉芽腫性疾患 24 : 21-30, 2004.
Medical*Online
3) Donsky AS, et al : Heart transplantation for undiagnosed cardiac sarcoidosis. Am J Cardiol 89 : 1447-1450, 2002.
PubMed
4) 日本サルコイドーシス/肉芽腫性疾患学会 : サルコイドーシスの診断基準と診断の手引き2006. サルコイドーシス/肉芽腫性疾患 26 : 77-82, 2006.
 
5) Iwai K, et al : Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn 43 (7-8) : 372-376, 1993.
 
6) Matsumori A, et al : Hypertrophic cardiomyopathy as a manifestation of cardiac sarcoidosis. Jpn Circ J 64 : 679-683, 2000.
PubMed
7) Okumura W, et al : Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 45 (12) : 1989-1998, 2004.
PubMed
8) Yamagishi H, et al : Identification of cardiac sarcoidosis with 13N-NH3/18F-FDG PET. J Nucl Med 44 : 1030-1036, 2003.
 
9) Shimada T, et al : Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med 110 (7) : 520-527, 2001.
PubMed
10) Uemura A, et al : Histologic diagnostic rate of cardiac sarcoidosis : evaluation of endomyocardial biopsies. Am Heart J 138 : 299-302, 1999.
PubMed
11) 寺崎文生, 北浦泰 : 心臓サルコイドーシスの病理形態. 呼吸と循環 54 : 947-954, 2006.
 
12) 日本サルコイドーシス/肉芽腫性疾患学会, 日本呼吸器学会, 日本心臓病学会, 日本眼科学会, 厚生省科学研究-特定疾患事業-びまん性肺疾患研究班編 : サルコイドーシス治療に関する見解-2003. サルコイドーシス/肉芽腫性疾患 23 : 105-114, 2003.
 
13) Yazaki Y, et al ; Central Japan Heart Study Group : Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 88 : 1006-1010, 2001.
 
14) 佐藤光希ほか : 両心室ペーシングが有効であった心サルコイドーシスによる難治性心不全の1例. J Cardiol 42 : 221-226, 2003.
 
15) Yager JE, et al : Recurrence of cardiac sarcoidosis in a heart transplant recipient. J Heart Lung Transplant 24 : 1988-1990, 2005.
 
P.455 掲載の参考文献
1) Dubrey SW, et al : Familial and primary (AL) cardiac amyloidosis : echocardiographically similar diseases with distinctly different clinical outcomes. Heart 78 : 74-82, 1997.
PubMed
2) Hongo M, et al : Comparison of electrocardiographic findings in patients with AL (primary) amyloidosis and in familial amyloid polyneuropathy and anginal pain and their relation to histopathologic findings. Am J Cardiol 85 : 849-853, 2000.
PubMed
3) Simons M, Isner JM : Assessment of relative sensitivities of non-invasive tests for cardiac amyloidosis in documented cardiac amyloidosis. Am J Cardiol 69 : 425-427, 1992.
 
4) Fattori R, et al : Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy. Am Heart J 136 : 824-830, 1998.
PubMed
5) Appleton CP, et al : Relation of transmitral flow velocity patterns to left ventricular diastolic function : new insights from a combined hemodynamic and Doppler echocardiographic study. J Am Coll Cardiol 12 : 426-440, 1988.
PubMed
6) Koyama J, et al : Usefulness of pulsed tissue Doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL (primary) amyloidosis. Am J Cardiol 89 : 1067-1071, 2002.
PubMed
7) Koyama J, et al : Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 107 : 2446-2452, 2003.
PubMed
8) Klein AI, et al : Comprehensive Doppler assessment of right ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 15 : 99-108, 1990.
 
9) Cueto-Garcia L, et al : Echocardiography findings in systemic amyloidosis : spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol 6 : 737-743, 1985.
PubMed
10) Klein AI, et al : Prognostic signhicance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation 83 : 808-816, 1991.
 
11) Palladini G, et al : Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107 : 2440-2445, 2003.
PubMed
P.459 掲載の参考文献
1) 豊岡照彦 : 神経・筋疾患に伴う心筋疾患一ジストロフィン関連糖蛋白 (DAGC) の欠損とその遺伝子治療の試み. 目でみる循環器病シリーズ14 心筋症 (松森昭編), p 198-205, メジカルビュー社, 2000.
 
2) Muntoni F : Cardiac complications of childhood myopathies. J Child Neurol 18 : 191-202, 2003.
PubMed
3) Cox GF, Kunkel LM : Dystrophies and heart disease. Curr Opin Cardiol 12 : 329-343, 1997.
PubMed
4) 尾形仁子 : 筋ジストロフィーの心不全診断の問題点. 神経内科 62 : 560-565, 2005.
 
5) Eagle M, et al : Survival in Duchenne muscular dystrophy : improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 12 : 926-929, 2002.
PubMed
6) Mori K, et al : Plasma levels of natriuretic peptide and echocardiographic parameters in patients with Duchenne's progressive muscular dystrophy. Pediatr Cardiol 23 : 160-166, 2002.
PubMed
7) 尾形仁子, 服部淳夫. 健康診断を契機に発見された拡張型心筋症の一例. 心エコー 7 : 684-687, 2003.
Medical*Online
8) Berko BA, Swift M : X-linked dilated Cardiomyopathy. N Engl J Med 316 : 1186-1191, 1987.
PubMed
9) Politano L, et al : Development of cardiomyopathy in female carrier of Duchenne and Becker muscular dystrophies. JAMA 275 : 1335-1338, 1996.
 
10) Ogata H, et al : A female carrier of Duchenne muscular dystrophy complicated with cardiomyopathy. Intern Med 39 : 34-38, 2000.
PubMed
11) Urtizberea JA, et al : Dilated cardiomyopathy and related cardiac disorders in muscular dystrophy. In : The Muscular Dystrophies (ed by Emery AEH), p 202-222, Oxford University Press, Oxford, 2001.
 
12) 林同文, 山崎力 : 大規模臨床トライアル結果を活かす. 特集 : うっ血性心不全の治療-新世紀への展開. Heart View 5 : 94-105, 2001.
 
13) Ishikawa Y, et al : Cardioprotection for Duchenne's muscular dystrophy. Am Heart J 137 : 895-902, 1999.
PubMed
14) Exner DV, et al : Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction : apost hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 33 : 916-923, 1999.
 
15) Ogata H, et al : Myocardial strain changes in Duchenne muscular dystrophy without overt cardiomyopathy. Int J Cardiol 115 : 190-195, 2007.
PubMed
P.463 掲載の参考文献
1) Richardson P, et al : Report of the 1995 World Health Organization/Intemational Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 93 : 841-842, 1996.
 
2) Desnick RJ, et al : α-galactosidase A deficiency : Fabry disease. In : The Metabolic and Molecular Bases of Inherited Disease, 8th ed (ed by Scriver CR, et al), p3733-3774, McGraw-Hill, New York, 2001.
 
3) Meikle PJ, et al : Prevalence of lysosomal storage disorders. JAMA 281 : 249-254, 1999.
PubMed
4) Nakao S, et al : An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 333 : 288-293, 1995.
PubMed
5) Sachdev B, et al : Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105 : 1407-1411, 2002.
PubMed
6) Chimenti C, et al : Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 110 : 1047-1053, 2004.
PubMed
7) Pieroni M, et al : Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 107 : 1978-1984, 2003.
PubMed
8) Kawano M, et al : Significance of asymmetric basal posterior wall thinning in patients with cardiac Fabry's disease. Am J Cardiol 99 : 261-263, 2007.
PubMed
9) Moon JCC, et al : Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease : Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 24 : 2151-2155, 2003.
PubMed
10) Takenaka T, et al : Characteristic yearly progression of electrocardiographic abnormalities in cardiac Fabry disease. Eur Heart J 23 (Suppl) : 257, 2002.
 
11) Pieroni M, et al : Fabry's disease cardiomyopathy : Echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. J Am Coll Cardiol 47 : 1663-1671, 2006.
PubMed
12) Eng CM, et al : Safety and efficacy of recombinant human a-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 345 : 9-16, 2001.
 
13) Weidemann F, et al : Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease : A prospective strain rate imaging study. Circulation 108 : 1299-1301, 2003.
PubMed
14) Beer M, et al : Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol 67 : 1515-1518, 2006.
 
15) Yoshimitsu M, et al : Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci USA 101 : 16909-16914, 2004.
PubMed
P.469 掲載の参考文献
1) Cohn JN, Tognoni G : A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 : 1667-1675, 2001.
PubMed
2) Pfeffer MA, et al : Effects of candesartan on mortality and morbidity in patients with chronic heart failure : the CHARM-Overall programme. Lancet 362 : 759-766, 2003.
PubMed
3) Kannel WB, et al : Role of diabetes in congestive heart failure : the Framingham study. Am J Cardiol 34 : 29-34, 1974.
PubMed
4) Varela-Roman A, et al : Influence of diabetes on the survival of patients hospitalized with heart failure : A 12-year study. Eur J Heart Fail 7 : 859-864, 2005.
PubMed
5) Haffner SM, et al : Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 : 229-234, 1998.
PubMed
6) Aguilar D, et al : Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction : The valsartan in acute myocardial infarction (VALIANT) trial. Circulation 110 : 1572-1578, 2004.
PubMed
7) Fang ZY, et al : Diabetic cardiomyopathy : evidence, mechanisms, and therapeutic implications. Endocr Rev 25 : 543-567, 2004.
PubMed
8) Fang ZY, et al : Echocardiographic detection of early diabetic myocardial desease. J Am Coll Cardiol 41 : 611-617, 2003.
 
9) Boyer JK, et al : Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 93 : 870-875, 2004.
PubMed
10) Fang ZY, et al : Screening for heart disease in diabetic subjects. Am Heart J 149 : 349-354, 2005.
PubMed
11) Marwick TH : Diabetic heart disease. Heart 92 : 296-300, 2006.
PubMed
12) Shiomi T, et al : Streptozotocin-induced hyperglycemia exacerbates left ventricular remodeling and failure after experimental myocardial infarction. J Am Coll Cardiol 42 : 165-172, 2003.
PubMed
13) Vasan RS, Levy D : Defining diastolic heart failure. A call for standardized diagnostic criteria. Circulation 101 : 2118-2121, 2000.
 
14) Yusuf S, et al : Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction : the CHARM-Preserved Trial. Lancet 362 : 777-781, 2003.
PubMed
15) Cleland JG, et al : The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27 : 2338-2345, 2006.
PubMed
P.473 掲載の参考文献
1) Piano MR : Alcoholic cardiomyopathy. Chest 121 : 1638-1650, 2002.
PubMed
2) 和泉徹ほか : アルコール性心筋疾患. 別冊日本臨牀 循環器症候群III, p 15-21, 日本臨牀社, 1996.
 
3) Lazarevic AM, et al : Early changes in left ventricular function in chronic asymptomatic alcoholics : relation to the duration of heavy drinking. J Am Coll Cardiol 35 : 1599-1606, 2000.
 
4) Wynne J, Braunwald E : Alcoholic cardiomyopathy. In : Braunwald's Heart Disease, 7th ed (ed by Zipes DP, et al), p 1666-1667, Saunders, Philadelphia, 2005.
 
5) Urbano-Marquez A, et al : The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 320 : 409-415, 1989.
PubMed
6) Koide T, Ozeki K : The incidence of myocardial abnormalities in man related to the level of ethanol consumption. Jpn Heart J 15 : 337-348, 1974.
 
7) Allen A : The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 19 : 529-542, 1992.
 
8) Schimmel KJ, et al : Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 30 : 181-191, 2004.
PubMed
9) Kremer LC, Caron HN : Anthracycline cardiotoxicity in children. N Engl J Med 351 : 120-121, 2004.
PubMed
10) 岡田義信 : アドリアマイシンによるうっ血性心不全. 新潟がんセンター病医誌 39 : 1-5, 2000.
 
11) Steinherz LJ, et al : Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266 : 1672-1677, 1991.
PubMed
12) Von Hoff DD, et al : Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91 : 710-717, 1979.
PubMed
13) Launchbury AP, Habboubi N : Epirubicin and doxorubicin : a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 19 : 197-228, 1993.
 
14) Bristow MR, et al : Ethcacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer 50 : 32-41, 1982.
PubMed
15) 岡田義信ほか : 心エコー図によるdoxorubicinの心毒性およびその適正な投与方法の検討. 癌と化学療法 24 : 2137-2141, 1997.
Medical*Online
P.478 掲載の参考文献
1) 日本透析医学会 : わが国の慢性透析療法の現況2005年12月31日現在.
 
2) Langendorf R, Pirani CL : The heart in uremia. The heart in uremia, An electrocardiograhic and pathologic study. Am Heart J 33 : 282-307, 1947.
 
3) Wacker N, Merrill JP : Uremic pericarditis and renal failure. JAMA 156 : 764-765, 1954.
 
4) Rostand SG, Rutsky EA : Pericarditis in end-stage renal disease : clinical characteristics and management. Semin Dial 2 : 25-30, 1989.
 
5) Gunukula SR, Spodick DH : Pericardial disease in renal patients. Semin Nephrol 21 : 52-56, 2001.
PubMed
6) Kumar S, Lesch M : Pericarditis in renal disease. Prog Cardiovasc Dis 22 : 357-369, 1980.
PubMed
7) Rostand SG, Rutsky EA : Pericarditis in end -stage renal disease. Cardiol Clin 8 : 701-707, 1990.
PubMed
8) 日本透析医学会 : わが国の慢性透析療法の現況1995年12月31日現在.
 
9) 日本透析医学会 : わが国の慢性透析療法の現況2000年12月31日現在.
 
10) Renfrew R, et al : Pericarditis and renal failure. Annu Rev Med 31 : 345-360, 1980.
PubMed
11) Alpert MA, Ravenscraft MD : Pericardial involvement in end-stage renal disease. Am J Med Sci 325 (4) : 228-236, 2003.
PubMed
12) Wood JE, Manhnensmith RL : Pericarditis associated with renal failure : evolution and management. Semin Dial 14 : 61-66, 2001.
 
13) Koshy E, et al : Uraemic constrictive pericraditis with a review of literature. J Assoc Physicians India 30 : 236-238, 1982.
 
14) Ludin AP : Recurrent uremic pericarditis : Amarker of inadequate dialysis, Semin Dial 3 : 5, 1990.
 
15) 田部井薫 : 心膜炎 (心嚢液貯留). 透析療法における心・血管系合併症と対策 (浅野泰編), p128-139, 日本メディカルセンター, 2001.
 
16) Zakynthinos E, et al : Uremic pericarditis with tamponade following prolonged continuous hemofiltration. Intensive Care Med 27 : 1958-1959, 2001.
PubMed
17) Spector D, et al : A controlled study of the effect of indomethacine in uremic pericarditis. Kidney Int 24 : 663-669, 1983.
 
18) Morimoto S, et al : The efficacy of indomethacin in the treatment of uremic pericarditis. Nippon Jinzo Gakkai Shi 37 : 140-144, 1995.
PubMed
19) Spaia S, et al : Managing refractory uraemic paricarditis with colchicine. Nephrol Dial Transplant 19 : 2422-2423, 2004.
 
P.484 掲載の参考文献
1) Gruberg L, et al : Incidence, management, and outcome of coronary artery perforation during percutaneus coronary intervention. Am J Cardiol 86 : 680-682, 2000.
 
2) Spodick DH : Threshold of pericardial constraint : the pericardial reserve volume and auxiliary pericardial functions. J Am Coll Cardiol 6 : 296-297, 1985.
PubMed
3) Spodick DH : The normal and diseased pericardium : current concepts of pericardial physiology, diagnosis and treatment. J Am Coll Cardiol 1 : 240-251, 1983.
PubMed
4) Spodick DH : Pericardial diseases. In : Heart Disease : A Textbook of Cardiovascular Medicine, 6th ed, Vol 2 (ed by Braunwald E, et al), p 1823-1876, WB Saunders, Philadelphia, 2001.
 
5) Shabetai R : Pericardial and cardiac pressure. Circulation 77 : 1-5, 1988.
PubMed
6) Cooper JP, et al : How do the clinical findings in patients with pericardial e血sions influence the success of aspiration? Br Heart J 73 : 351-354, 1995.
 
7) Appleton CP, et al : Cardiac tamponade and pericardial effusion : respiratory variation in transvalvular flow velocities studied by Doppler echocardiography. J Am Coll Cardiol 11 : 1020-1030, 1988.
PubMed
8) Ramsaran EK : Exacebated tamponade : deterioration of cardiac function by lowering excessive arterial pressure in hypertensive cardiac tamponade. Cardiology 86 : 77-79, 1995.
 
9) Bommer WJ, et al : Tamponade in patients undergoing cardiac surgery : aclinical-echocardiographic diagnosis. Am Heart J 130 : 1216-1223, 1995.
 
10) Hancock EW : Subacute effusive-constrictive pericarditis. Circulation 43 : 183-192, 1971.
PubMed
11) Pepi M, et al : Pericardial effusion after cardiac surgery : incidence, site, size, and haemodynamic consequences. Br Heart J 72 : 327-331, 1994.
PubMed
12) Merce J, et al : Should pericardial drainage be performed routinely in patients who have a large pericardial effusion without tamponade? Am J Med 105 : 106-109, 1998.
PubMed
13) Spodick DH : Medical treatment of cardiac tamponade. In : Curaintensiva Cardiologica (ed by Catureli G), p 265 -268, TIPAR Poligrafica, Rome, 1991.
 
14) Klopfenstein HS, et al : Influence of naloxone on response to acute cardiac tamponade in conscious dogs. Am J Physiol 259 : H512-H517, 1990.
PubMed
15) Hashim R, et al : Fluid resuscitation-induced cardiac tamponade. Trauma 53 : 1183-1184, 2002.
PubMed
P.489 掲載の参考文献
1) Bush CA, et al : Occult constrictive pericardial disease : Diagnosis by rapid volume expansion and correction by pericardiectomy. Circulation 56 : 924-930, 1977.
PubMed
2) 泉司郎ほか : 収縮性心膜炎における心臓血液流入異常significance of disturbances of cardiac filling in constrictive pericarditis. J Cardiol 19 : 529-539, 1989.
 
3) Killian DM, et al : Constrictive pericarditis after cardiac surgery. Am Heart J 118 : 563-568, 1989.
PubMed
4) Hancock EW : Subacute effusive-constrictive pericarditis. Circulation 43 : 183-192, 1971.
PubMed
5) McCaughan BC, et al : Early and late results of pericardiectomy for constrictive pericarditis. J Thorac Cardiovasc Surg 89 : 340 -350, 1985.
 
6) Ling LH, et al : Constrictive pericarditis in the modern era. Evolving clinical spectrum and impact on outcome after pericardiectomy. Circulation 100 : 1380-1386, 1999.
PubMed
7) 松原広己ほか : 収縮性心膜炎における心膜剥離術不成功例の術前予測. J Cardiol 25 : 89-94, 1995.
 
P.494 掲載の参考文献
1) 山本和男ほか : 心臓弁膜症546例の病因. 心臓 24 : 917-924, 1992.
 
2) Otto CM, et al : Histological and immunohistochemical studies. Circulation 90 : 844-853, 1994.
PubMed
3) Agmon Y, et al : Aortic valve sclerosis and aortic atherosclerosis : different manifestations of the same disease? J Am Coll Cardiol 38 : 827-834, 2001.
 
4) O'Brien KD, et al : Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 106 : 2224-2230, 2002.
PubMed
5) Ross J Jr, Braunwald E : Aortic stenosis. Circulation 38 (suppl V) : V61-V67, 1968.
 
6) 松田暉ほか : 弁膜疾患の非薬物治療に関するガイドライン. Circulation Journal 66 : 1276-1280, 2002.
 
7) Bonow RO, et al : ACC/AHA 2006 guidelines for the management of patients with valvular heart disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) : developed in collaboration with the Society of Cardiovascular Anesthesiologists : endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 114 : e84-231, 2006.
 
8) Monin JL, et al : Low-gradient aortic stenosis : operative risk stratification and predictors for longteml outcome : a multicenter study using dobutamine stress hemodynamics. Circulation 108 : 319-324, 2003.
PubMed
9) Lin SS, et al : Dobutamine stress Doppler hemodynamics in patients with aortic stenosis : Feasibility, safety, and surgical correlations. Am Heart J 136 : 1010-1016, 1998.
PubMed
10) Monin JL, et al : Low-gradient aortic stenosis : operative risk stratification and predictors for longterm outcome : a multicenter study using dobutamine stress hemodynamics. Circulation 108 : 319-324, 2003.
PubMed
11) Cheitlin MD, et al : ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography-summary article : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Coll Cardiol 42 : 954-970, 2003.
 
12) Sundt TM, et al : Quality of life after aortic valve replacement at the age of > 80 years. Circulation 102 (Suppl III) : 70-74, 2000.
 
13) Banbury MK, et al : Age and valve size effect on the Iong-term durability of the Carpentier-Edwards aortic pericardial bioprostheses. Ann Thorac Surg 72 : 753-757, 2001.
 
14) David TE, et al : Late results of heart valve replacement with the Hancock II bioprosthesis. J Thorac Cardiovasc Surg 121 : 268-278, 2001.
PubMed
15) Mullnany CJ : Aortic valve surgery in the elderly. Cardiol Rev 8 : 333-339, 2000.
 
P.500 掲載の参考文献
1) Boudoulas H, Gravanis MB : Valvular heart disease. In : Cardiovascular disorders : Pathogenesis and Pathopysiology (ed by Gravanis MB), C. V. Mosby, St Louis, 1993.
 
2) Grossman W : Cardiac hypertrophy : usefU1 adaptation or pathologic process? Am J Med 69 : 576-584, 1980,
 
3) Taniguchi K, et al : Left ventricular ejection performance, wall stress, and contractile state in aortic regurgitation before and after aortic valve replacement. Circulation 82 : 798-807, 1990.
 
4) Rapaport E : Natural history of aortic and mitral valve disease. Am J Cardiol 35 : 221-227, 1975.
PubMed
5) Aronow WS, et al : Prognosis of patients with heart failure and unoperated severe aortic valvular regurgitation and relation to ejection fraction. Am J Cardiol 74 : 286-288, 1994.
PubMed
6) Schwarz F, et al : Long-term prognosis of drug and surgery treated patients with acquired aortic valve diseases : survival statistics and multivariate Cox regression analysis. Z Kardiol 74 : 598-603, 1985.
PubMed
7) Dujardin KS, et al : Mortahty and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study. Circulation 99 : 1851-1857, 1999.
PubMed
8) Bonow RO, et al : ACC/AHA guidelines for the management of patients with valvular heart disease : Areport of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). J Am Coll Cardiol 32 : 1486-1588, 1998.
 
9) Henry WL, et al : Observations on the optimum time for operative intervention for aortic regurgitation. I. Evaluation of the results of aortic valve replacement in symptomatic patients. Circulation 61 : 471-483, 1980.
PubMed
10) Taniguchi K, et al : Preoperative left ventricular function : minimal requirement for successful late results of valve replacement of aortic regurgitation. J Am Coll Cardiol 10 : 510-518, 1987.
PubMed
11) Taniguchi K, et al : Depressed myocardial contractility and normal ejection performance after aortic valve replacement in patients with aortic regurgitation. J Thorac Cardiovasc Surg 98 : 258-265, 1989.
PubMed
12) 弁膜症の非薬物治療に関するガイドライン. Jpn Circ J 66 (suppl, IV) : 1261-1350, 2002.
 
13) Carpentier A : Cardiac valve surgery-the "French correction". J Thorac Cardiovasc Surg 86 : 323-337, 1983.
PubMed
14) Trusler GA, et al : Repair of ventricular septal defect with aortic insufficiency. J Thorac Cardiovasc Surg 66 : 394-403, 1973.
PubMed
15) Duran C, et al : Indications and limitations of aortic valve reconstruction. Ann Thorac Surg 52 : 447-453, 1991,
PubMed
16) Duran CM : Present status of reconstructive surgery for aortic valve disease. J Card Surg 8 : 443-452, 1993.
PubMed
17) Fraser CD Jr, et al : Repair of insufficient bicuspid aortic valves. Ann Thorac Surg 58 : 386-390, 1994.
PubMed
18) Kazui T, et al ; Japanese Association for Thoracic Surgery Committee for Scientific Affairs : Thoracic and cardiovascular surgery in Japan during 2004. Jpn J Thorac Cardiovasc Surg 54 : 363-385, 2006.
PubMed
P.506 掲載の参考文献
1) Gordis L : The virtual disappearance of rheumatic fever in the United States : lessons in the rise and fall of disease. T Duckett Jones memorial lecture. Circulation 72 : 1155-1162, 1985.
 
2) Flachskampf EA, et al : Aortic regurgitation shortens Doppler pressure half-time in mitral stenosis : clinical evidence, in vitro simulation and theoretic analysis. J Am Coll Cardiol 16 : 396-404, 1990.
 
3) Henry WL, et al : Measurement of mitral orifice area in patients with mitral valve disease by real-time, two-dimensional echocardiography. Circulation 51 : 827-831, 1975.
PubMed
4) Hatle L, et al : Noninvasive assessment of atrioventricular pressure haif-time by Doppler ultrasound. Circulation 60 : 1096-1104, 1979.
 
5) Inoue K, et al : Clinical application of transvenous mitral commissurotomy by a new balloon catheter. J Thorac Cardiovasc Surg 87 : 394-402, 1984.
PubMed
6) Wilkins GT, et al : Percutaneous balloon dilatation of the mitral valve : an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J 60 : 299-308, 1988.
PubMed
7) Crawford MH, et al : Determinants of survival and left ventricular performance after mitral valve replacement. Department of Veterans Affairs Cooperative Study on Valvular Heart Disease. Circulation 81 : 1173-1181, 1990.
 
P.510 掲載の参考文献
1) Enriquez-Sarano M, et al : Progression of mitral regurgitation : a prospective Doppler echocardiographic study. J Am Coll Cardiol 34 : 1137-1144, 1999.
PubMed
2) Grigioni F, et al : Sudden death in mitral regurgitation due to flail leaflet. J Am Coll Cardiol 34 (7) : 2078-2085, 1999.
PubMed
3) Grigioni F, et al : Ischemic mitral regurgitation : long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 103 : 1759-1764, 2001.
PubMed
4) Otsuji Y, et al : Insights from three-dimensional echocardiography into the mechanism of functional mitral regurgitation : direct in vivo demonstration of altered leaflet tethering geometry. Circulation 96 : 1999-2008, 1997.
PubMed
5) Otsuji Y, et al : Isolated annular dilation does not usually cause important functional mitral regurgitation : comparison between patients with lone atrial fibrillation and those with idiopathic or ischemic cardiomyopathy. J Am Coll Cardiol 39 : 1651-1656, 2002.
PubMed
6) Uemura T, et al : Papillary muscle dysfunction attenuates ischemic mitral regurgitation in patients with localized basal inferior left ventricular remodeling : insights from tissue Doppler strain imaging. J Am Coll Cardiol 46 : 113-119, 2005.
PubMed
7) Keren G, et al : Effect of isometric exercise on cardiac performance and mitral regurgitation in patients with severe congestive heart failure. Am Heart J 118 (5 Pt 1) : 973-979, 1989.
 
8) Tei C, et al : Acute hemodynamic improvement by thermal vasodilation in congestive heart failure. Circulation 91 (10) : 2582-2590, 1995.
PubMed
9) Breithardt OA, et al : Acute effects of cardiac resynchronization therapy on functional mitral regurgitation in advanced systolic heart failure. J Am CoU Cardiol 41 : 765-770, 2003.
 
10) Hickey MS, et al : Current prognosis of ischemic mitral regurgitation. Implications for future management. Circulation 78 (3 Pt 2) : 151-159, 1988.
 
11) Aklog L, et al : Does coronary artery bypass grafting alone correct moderate ischemic mitral regurgitation? Circulation 104 (12 suppl 1) : I68-I75, 2001.
 
12) Bolling SF, et al : Intermediate-term outcome of mitral reconstruction in cardiomyopathy. J Thorac Cardiovasc Surg 115 : 381-386, 1998.
PubMed
13) Hung J, et al : Mechanism of recurrent ischemic mitral regurgitation after annuloplasty : continued LV remodeling as a moving target. Circulation 110 (11 Suppl 1) : II85 -II90, 2004.
 
14) Kuwahara E, et al : Mechanism of recurrent/persistent ischemic/functional mitral regurgitation in the chronic phase after surgical annuloplasty : importance of augmented posterior leaflet tethering. Circulation 114 (1 suppl) : I529-I534, 2006.
 
15) Ueno T, et al : A new surgical approach to reduce tethering in ischemic mitral regurgitation by relocation of separate heads of the posterior papillary muscle. Ann Thorac Surg 81 : 2324-2325, 2006.
PubMed
P.516 掲載の参考文献
1) Bernal JM, et al : Tricuspid valve repair : an old disease, a modern experience. Ann Thorac Surg 78 : 2069-2074, 2004.
PubMed
2) Fukuda S, et al : Three-dimensional geometry of the tricuspid annulus in healthy subjects and in patients with functional tricuspid regurgitation : a real-time, 3-dimensional echocardiographic study. Circulation 114 : 1492-1498, 2006.
 
3) Ton-Nu TT, et al : Geometric determinants of functional tricuspid regurgitation : insights from 3-dimensional echocardiography. Circulation 114 : 143-149, 2006.
PubMed
4) Matsuyama K, et al : Predictors of residual tricuspid regurgitation after mitral valve surgery. Ann Thorac Surg 75 : 1826-1828, 2003.
PubMed
5) King RM, et al : Surgery for tricuspid regurgitation late after mitral valve replacement. Circulation 70 : I193-I197, 1984.
PubMed
6) Dreyfus GD, et al : Secondary tricuspid regurgitation or dilatation : which should be the criteria for surgical repair? Ann Thorac Surg 79 : 127-132, 2005.
 
7) Tang GH, et al : Tricuspid valve repair with an annuloplasty ring results in improved long-term outcomes. Circulation 114 : I577-I581, 2006.
PubMed
8) McCarthy PM, et al : Tricuspid valve repair : durability and risk factors for failure. J Thorac Cardiovasc Surg 127 : 674-685, 2004.
PubMed
9) Fukuda S, et al : Tricuspid valve tethering predicts residual tricuspid regurgitation after tricuspid annuloplasty. Circulation 111 : 975-979, 2005.
PubMed
10) Fukuda S, et al : Determinants of recurrent or residual functional tricuspid regurgitation after tricuspid annuloplasty. Circulation 114 : I582-I587, 2006.
 
11) Filsoufi F, et al : A three-dimensional ring annuloplasty for the treatment of tricuspid regurgitation. Ann Thorac Surg 81 : 2273-2277, 2006.
PubMed
12) Rizzoli G, et al : Biological or mechanical prostheses in tricuspid position? A meta-analysis of intra-institutional results. Ann Thorac Surg 77 : 1607-1614, 2004.
 
13) Filsoufi F, et al : Long-term outcomes of tricuspid valve replacement in the current era. Ann Thorac Surg 80 : 845-850, 2005.
PubMed
P.521 掲載の参考文献
1) Anderson DW, et al : Prevalent myocarditis at necropsy in the acquired immunodeficiency syndrome. J Am Coll Cardiol 11 : 792-799, 1988.
PubMed
2) Barbaro G, et al : Incidence of dilated cardiomyopathy and detection of HrV in myocardial cells of HIV-positive patients. Gruppo Italiano per lo Studio Cardiologico dei Pazienti Affetti da AIDS. N Engl J Med 339 : 1093-1099, 1998.
 
3) Lewes D, et al : Symptomless myocarditis and myalgia in viral and Mycoplasma pneumoniae infections. Br Heart J 36 : 924-932, 1974.
PubMed
4) 松井明美ほか : 学校心電図検診で発見された無症候性心筋炎の1例. 小児科臨床 51 : 210-214, 1998.
Medical*Online
5) Kato S, et al : Use of percutaneous cardiopulmonary support of patients with fulminant myocarditis and cardiogenic shock for improving prognosis. Am J Cardiol 83 : 623-625, 1999.
PubMed
6) Kato S, et al : Successful high-dose intravenous immunoglobulin therapy for a patients with fulminant myocarditis. Heart Vessels 22 : 48-51, 2007.
PubMed
7) Hiramitsu S, et al : Clinical course of myocarditis through the acute, fulminant and fatal chronic stages : an autopsy case. Circ J 70 : 1086-1090, 2006.
PubMed
8) Woodruff JF : Viral myocarditis. A review. Am J Pathol 101 : 425-484, 1980.
PubMed
9) Clements GB : Characteristics of viruses inducing cardiac disease. In : Viral Infections of the Heart (ed by Banatvala JE), p 1-21, Hodder and Stoughton, London, 1993.
 
10) Matsumori A, et al : Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation 92 : 2519-2525, 1995.
PubMed
11) Shioi T, et al : Persistent expression of cytokine in the chronic stage of viral myocarditis in mice. Circulation 94 : 2930-2937, 1996.
PubMed
12) Matsumori A : Hepatitis C virus and cardiomyopathy. Herz 25 : 249-254, 2000.
PubMed
13) Lauer B, et al : Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol 30 : 1354-1359, 1997.
PubMed
14) Morimoto S, et al : Role of myocardial interstitial edema in conduction disturbances in acute myocarditis. Heart Vessels 21 : 356-360, 2006.
PubMed
15) Hiramitsu S, et al : Significance of transient left ventricular wall thickening in acute lymphocytic myocarditis. Heart Vessels 22 : 25-29, 2007.
PubMed
16) Gore I, et al : Myocarditis. In : Pathology of the Heart and Blood Vessels (ed by Gould SE), p 731-759, Thomas, Illinois, Springfield, 1968.
 
17) Atkinson JB, et al : Cardiac infections in the immunocompromised host. Cardiol Clin 2 : 671-686, 1984.
PubMed
18) Sands MJ Jr, et al : Pericarditis and perimyocarditis associated with active Mycoplasma pneumoniae infection. Ann Intern Med 86 : 544-548, 1977.
PubMed
19) Ponka A : Carditis associated with Mycoplasma pneumoniae infection. Acta Med Scand 206 : 77-86, 1979.
PubMed
20) Lind K : Manifestations and complications of Mycoplasma pneumoniae disease : a review. Yale J Biol Med 56 : 461-468, 1983.
PubMed
21) 高橋徹ほか : Adams-Stokes発作で発見されたマイコプラズマ心筋炎と考えられた1例. 小児科臨床 44 : 1985-1990, 1991.
Medical*Online
22) 森本紳一郎 : マイコプラズマ心筋炎. 別冊日本臨牀 循環器症候群III, p211-214, 日本臨牀社, 1996.
 
23) Sekiguchi M, et al : Age-associated myocardial changes in various heart disease. A clinicopathologic analysis in biopsied and autopsied myocardium. Jpn Circ J 50 : 1023-1032, 1986.
PubMed
24) Rosenbaum H, Linn HJ : Tuberculosis of myocardium. Am J Clin Pathol 18 : 162-166, 1948.
 
25) Atkinson JB, et al : Cardiac fungal infections : review of autopsy findings in 60 patients. Hum Pathol 15 : 935-942, 1984.
PubMed
26) Walsh TJ, et al : Fungal infections of the heart : analysis of 51 autopsy cases. Am J Cardiol 45 : 357-366, 1980.
PubMed
27) Yotsukura M, et al : Review of a case of tsutsugamushi disease showing myocarditis and confirmation of Rickettsia by endomyocardial biopsy. Jpn Circ J 55 : 149-153, 1991.
PubMed
28) Boss JH, et al : Unusual manifestations of syphilitic cardiovascular disease. Ann Intern Med 55 : 824-831, 1961.
PubMed
29) Theologides A, Kennedy BJ : Toxoplasmic myocarditis and pericarditis. Am J Med 47 : 169-174, 1969.
PubMed
30) Puigbo JJ, et al : Chagas' disease. In : Overview and Perspective (ed by Olsen EGJ, et al), p 347-360, University of Tokyo Press, Tokyo, 1990.
 
31) Andrade ZA : Pathogenesis of Chagas' disease. Res Immunol 142 (2) : 126-129, 1991.
PubMed
32) Hardy WR, Anderson RE : The hypereosinophilic syndromes. Ann Intern Med 68 : 1220-1229, 1968.
PubMed
33) Take M, et al : Clinical spectrum and endomyocardial biopsy findings in eosinophilic heart disease. Heart Vessels Suppl 1 : 243-249, 1985.
PubMed
34) Sekiguchi M, et al : Ultrastructural features of the endomyocardium in patients with eosinophilic heart disease. An Endomyocardial biopsy study. Jpn Circ J 48 : 1375-1382, 1984.
PubMed
P.526 掲載の参考文献
1) 和泉徹ほか : 循環器病の診断と治療に関するガイドライン. 急性および慢性心筋炎の診断・治療に関するガイドライン. Circ J 68 (Suppl 4) : 1231-1272, 2004.
 
2) Kanzaki Y, et al : Myocardial inflammatory cell infiltrates in cases of dilated cardiomyopathy as a determinant of outcome following partial left ventriculectomy. Jpn Circ J 65 : 797-802, 2001.
PubMed
3) Mason JW, et al : A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 333 : 269-275, 1995.
PubMed
4) Kodama M, et al : Early and long-term mortality of the clinical subtypes of myocarditis. Jpn Circ J 65 : 961-964, 2001.
PubMed
5) Kodama M, et al : Characteristics of giant cells and factors related to the formation of giant cells in myocarditis. Circ Res 69 : 1042-1050, 1991.
 
6) Cooper LT, et al : Idiopathic giant cell myocarditis-natural history and treatment. N Engl J Med 336 : 1860-1866, 1997.
PubMed
7) Okura Y, et al : A clinical and histologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol 41 : 322-328, 2003.
PubMed
P.530 掲載の参考文献
1) Cohn JN : Current therapy of the failing heart. Circulation 78 : 1099-1107, 1988.
PubMed
2) Wagner HR, et al : Clinical course in aortic stenosis. Circulation 56 (Suppl 1) : 147-56, 1977.
 
3) Graham TP, et al : Long-term outcome in congenitally corrected transposition of the great arteries ; a multi -institutional study. J Am Coll Cardiol 36 : 255-261, 2000.
PubMed
4) Jones M, Ferrans VJ : Myocardial degeneration in congenital heart disease. Comparison of morphologic findings in young and old patients with congenital heart disease associated with muscular obstruction to right ventricular outflow. Am J Cardiol 39 : 1051-1063, 1977.
 
5) Bolger AP, et al : Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 106 : 92-99, 2002.
PubMed
6) Hunt SA, et al : ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) : developed in collaboration with the American College of Chest Physicians and the Intemational Society for Heart and Lung Transplantation : endorsed by the Heart Rhythm Society. Circulation 112 : e154-e235, 2005.
 
7) Vonder Muhll I, et al : Applying standard therapies to new targets : the use of ACE inhibitors and β-blockers for heart failure in adults with congenital heart disease. Int J Cardiol 97 (Suppl 1) : 25-33, 2004.
 
8) Hechter SJ, et al : Angiotensin-converting enzyme inhibitors in adults after the Mustard procedure. Am J Cardiol 87 : 660-663, 2001.
PubMed
9) Hopkins WE, Kelly DP : Angiotensin-converting enzyme inhibitors in adults With cyanotic congenital heart disease. Am J Cardiol 77 : 439-440, 1996.
PubMed
10) Lester SJ, et al : Effects of losartan in patients with a systemically functioning morphologic right ventricle after atrial repair of transposition of the great arteries. Am J Cardiol 88 : 1314-1316, 2001.
PubMed
11) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 : 709-717, 1999.
PubMed
12) The Digitalis Investigation Group : The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 : 525-533, 1997.
 
13) Abraham WT, et al : Cardiac resynchronization in chronic heart failure. N Engl J Med 346 : 1845-1853, 2002.
PubMed
14) Bacha EA, et al : Ventricular resynchronization by multisite pacing improves myocardial performance in the postoperative single-ventricle patient. Ann Thorac Surg 78 : 1678-1683, 2004.
PubMed
P.536 掲載の参考文献
1) Suys BE, et al : Female children and adolescents with type 1 diabetes have more pronounced early echocardiographic signs of diabetic cardiomyopathy. Diabetes Care 27 (8) : 1947-1953, 2004.
PubMed
2) Quan SF, et al : Cardiovascular consequences of sleep-disordered breathing : past, present and future : report of a workshop from the National Center on Sleep Disorders Research and the National Heart, Lung, and Blood Institute. Circulation 109 (8) : 951-957, 2004.
PubMed
3) Lanfranchi PA, et al : Central sleep apnea in left ventricular dysfunction : prevalence and implications for arrhythmic risk. Circulation 107 (5) : 727-732, 2003.
PubMed
4) Okin PM, et al : Time-voltage QRS area of the 12-lead electrocardiogram : detection of left ventricular hypertrophy. Hypertension 31 (4) : 937-942, 1998.
PubMed
5) Devereux RB, Reichek N : Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 55 (4) : 613-618, 1977.
PubMed
6) Sundstrom J, et al : Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation 103 (19) : 2346-2351, 2001.
 
7) Drazner MH, Reichek N : Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years : the Cardiovascular Health Study. J Am Coll Cardiol 43 (12) : 2207-2215, 2004.
 
8) Gandhi SK, et al : The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 344 (1) : 17-22, 2001.
PubMed
9) Yu suf S, et al : Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction : the CHARM-Preserved Trial. Lancet 362 (9386) : 777-781, 2003.
 
10) Yip GWK, et al : Diastolic dysfunction and hypertension. N Engl J Med 344 (18) : 1401-1402, 2001.
 
11) Krishnan P, et al : Treatment of hypertension for patients with diastolic dysfunction. Curr Opin Cardiol 18 (4) : 272-277, 2003.
PubMed
12) Zile MR, et al : Diastolic heart failure-Abnormalities in active relaxation and passive stiffhess of the left ventricle. N Engl J Med 350 (19) : 1953-1959, 2004.
 
13) Redfield MM, et al : Burden of systolic and diastolic ventricular dysfunction in the community : appreciating the scope of the heart failure epidemic. JAMA 289 (2) : 194-202, 2003.
PubMed
14) Jiang Y, et al : The relation between left ventricular geometric patterns and left ventricular midwall mechanics in hypertensive patients. Hypertens Res 25 (2) : 191-195, 2002.
PubMed
15) Yip G, et al : Left ventricular long axis function in diastolic heart failure is reduced in both diastole and systole : time for a redefinition? Heart 87 (2) : 121-125, 2002.
PubMed
16) Borges MCC, et al : Longitudinal mitral annulus velocities are reduced in hypertensive subjects with or without left ventricle hypertrophy. Hypertension 47 (5) : 854-860, 2006.
PubMed
17) Kass DA : Ventricular arterial stiffening : integrating the pathophysiology. Hypertension 46 (1) : 185-193, 2005.
PubMed
18) Ishikawa J, et al : Collagen metabolism in extracellular matrix may be involved in arterial stiiifrless in older hypertensive patients with left ventricular hypertrophy. Hypertens Res 28 (12) : 995-1001, 2005.
PubMed
19) Lubien E, et al : Utility of B-natriuretic peptide in detecting diastolic dysfunction : comparison with Doppler velocity recordings. Circulation 105 (5) : 595-601, 2002.
PubMed
20) Yamaguchi H, et al : Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 43 (1) : 55-60, 2004.
PubMed
21) Sakata Y, et al : Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart failure. J Hypertens 19 (10) 11905-1912, 2001.
 
22) Liu JE, et al : Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure. Ann Intern Med 131 (8) : 564-572, 1999.
PubMed
23) Kario K, et al : Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives : a prospective study. Circulation 107 (10) : 1401-1406, 2003.
PubMed
24) Gosse P, et al : Blood pressure surge on Hsing. J Hypertens 22 (6) : 1113-1118, 2004.
 
25) Levy D, et al : The progression from hypertension to congestive heart failure. JAMA 275 (20) : 1557-1562, 1996.
PubMed
26) Vasan RS, et al : Congestive heart failure in subjects With normal versus reduced left ventricular ejection fraction : prevalence and mortality in a population-based cohort. J Am Coll Cardiol 33 (7) : 1948-1955, 1999.
 
27) Owan TE, et al : Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (3) : 251-259, 2006.
PubMed
28) Bhatia RS, et al : Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355 (3) : 260-269, 2006.
 
29) Bendjelid K, et al : Does continuous positive airway pressure by face mask improve patients with acute cardiogenic pulmonary edema due to left ventricular diastolic dysfunction? Chest 127 (3) : 1053-1058, 2005.
PubMed
30) Wong CY, et al : Alterations of left ventricular myocardial characteristics associated with obesity. Circulation 110 (19) : 3081-3087, 2004.
 
31) Eguchi K, et al : Type 2 diabetes is associated with left ventricular concentric remodeling in hypertensive patients. Am J Hypertens 18 (1) : 23-29, 2005.
PubMed
32) Piccini Jp, et al : New insights into diastolic heart failure : role of diabetes mellitus. Am J Med 116 (Suppl 5A) : 64S-75S, 2004.
 
33) Arnold JMO, et al : Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 107 (9) : 1284-1290, 2003.
PubMed
34) Devereux RB, et al : Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol : the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 110 (11) : 1456-1462, 2004.
PubMed
35) Philbin EF, et al : Systolic versus diastolic heart failure in community practice : clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 109 (8) : 605-613, 2000.
PubMed
36) Setaro JF, et al : Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 66 (12) : 981-986, 1990.
PubMed
37) Terpstra WF, et al : Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients : the ELVERA trial. J Hypertens 19 (2) : 303-309, 2001.
 
38) The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic : The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (23) : 2981-2997, 2002.
PubMed
39) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (10) : 709-717, 1999.
PubMed
40) Mottram PM, et al : Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110 (5) : 558-565, 2004.
PubMed
41) Ouzan J, et al : The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 15 (4) : 333-339, 2002.
PubMed
42) Pickering TG, et al : Masked hypertension. Hypertension 40 (6) : 795-796, 2002.
PubMed
43) Hoshide S, et al : Associations between nondipping of nocturnal blood pressure decrease and cardiovascular target organ damage in strictly selected community-dwelling normotensives. Am J Hypertens 16 (6) : 434-438, 2003.
PubMed
44) Tamura N, et al : Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 97 (8) : 4239-4244, 2000.
PubMed
45) Tsuruda T, et al : Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 91 (12) : 1127-1134, 2002.
PubMed

XXV その他病能・年齢層の心不全の臨床的事項

P.544 掲載の参考文献
1) Bruyne LK : Mechanisms and management of diuretic resistance in congestive heart failure. Postgrad Med J 79 : 268 -271, 2003.
 
2) Aquilani R, et al : Is nutritional intake adequate in chronic heart failure patients? J Am Coll Cardiol 42 : 1218-1223, 2003.
PubMed
3) Kenchaiah S, et al : Obesity and the risk of heart failure. N Engl J Med 347 : 305-313, 2002.
PubMed
4) Horwich TB, et al : The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 38 : 789-795, 2001.
PubMed
5) Educational Modules on Heart Failure : II How to Follow a Low-Sodium Diet Heart Failure Society of America, 2002.
 
6) Bristow MR, et al : Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 : 2140-2150, 2004.
 
7) James K, et al : Heart Transplantation, p 883, illustrated, Churchill Livingstone, New York, 2002.
 
P.548 掲載の参考文献
1) Huhta JC : Guidelines for the evaluation of heart failure in the fetus with or without hydrops. Pediatr Cardiol 25 : 274-286, 2004.
PubMed
2) Falkensammer CB, et al : Fetal congestive heart failure : correlation of Tei-index and Cardiovascular-score. J Perinat Med 29 : 390-398, 2001.
 
3) Tulzer G, et al : Doppler in non-immune hydrops fetalis. Ultrasound Obstet Gynecol 4 : 279-283, 1994.
PubMed
4) Tulzer G, et al : Diastolic function of the fetal heart during second and third trimester : a prospective longitudinal Doppler-echocardiographic study. Eur J Pediatr 153 : 151-154, 1994.
PubMed
5) Kanzaki T, Chiba Y : Evaluation of the preload condition of the fetus by inferior vena caval blood flow pattern. Fetal Diagn Ther 5 : 168-174, 1990.
PubMed
6) Rizzo G, et al : Inferior vena cava flow velocity waveforms in appropriate-and small-for-gestational-age fetuses. Am J Obstet Gynecol 166 : 1271-1280, 1992.
PubMed
7) Rizzo G, et al : Ductus venosus velocity waveforms in appropriate and small for gestational age fetuses. Early Hum Dev 39 : 15-26, 1994.
PubMed
8) Mahle WT, et al : Echocardiographic evaluation of the fetus with congenital cystic adenomatoid malformation. Ultrasound Obstet Gynecol 16 : 620-624, 2000.
PubMed
9) Respondek ML, et al : The prevalence and clinical significance of fetal tricuspid valve regurgitation with normal heart anatomy. Am J Obstet Gynecol 171 : 1265-1270, 1994.
PubMed
10) Hornberger LK, et al : Tricuspid valve disease with significant tricuspid insufficiency in the fetus : diagnosis and outcome. J Am Coll Cardiol 17 : 167-173, 1991.
PubMed
11) Tulzer G, et al : Doppler in the evaluation and prognosis of fetuses with tricuspid regurgitation. J Maternal Fetal Invest 1 : 15-18, 1991.
 
12) Stale H, et al : Aortic diameter pulse waves and blood flow velocity in the small, for gestational age, fetus. Ultrasound Med Biol 17 : 471-478, 1991.
PubMed
P.553 掲載の参考文献
1) 仁志田博司 : 循環器系の基礎と臨床. 新生児学入門, 第3版, p 271-289, 医学書院, 2003.
 
2) 中畑龍俊 (監) : NICUベッドサイドの診断と治療, p 75, 金芳堂, 2003.
 
3) 豊島勝昭 : 心エコー検査による超低出生体重児の左心機能評価. 周産期医学 35 : 1091-1095, 2005.
 
4) 川滝元良ほか : 心不全に対する輸液管理. Neonatal Care2003年秋季増刊, p 114-119, メディカ出版, 2003.
 
5) 中澤誠 : 小児心不全の内科的治療. 小児科 41 : 2323-2329, 2000.
 
6) 濱島崇ほか : 低出生体重児とステロイド. 周産期医学 31 : 1377-1380, 2001.
 
7) 豊島勝昭 : 心不全時の輸液療法. 周産期医学 32 : 1483-1488, 2002.
 
8) 増谷聡ほか : ハンプ投与が奏効した後負荷不適合の超低出生体重児の2例. 日本未熟児新生児学会雑誌 15 : 241-245, 2003.
 
9) 瀧川逸朗 : 心不全の診断と治療. 周産期医学 35 : 1086-1090, 2005.
 
10) 小児心不全薬物療法ガイドライン. 日小循誌 17 : 501-512, 2001.
 
P.557 掲載の参考文献
1) Ho KK, et al : The epidemiology of heart failure : the Framingham Study. J Am Coll Cardiol 22 : 6A-13A, 1993.
PubMed
2) Tsuchibashi M, et al : Clinical characteristics and prognosis of hospitalized patients with congestive heart failure-a study in Fukuoka, Japan-. Jpn Circ J 64 : 953-959, 2000.
 
3) Passik CS, et al : Temporal changes in the causes of aortic stenosis : a surgical pathologic study of 646 cases. Mayo Clin Proc 62 : 119-123, 1987.
PubMed
4) Go AS, et al : Prevalence of diagnosed atrial fibrillation in adults : national implications for rhythm management and stroke prevention : the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285 : 2370-2375, 2001.
PubMed
5) Mahon NG, et al : The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol 40 : 1106-1113, 2002.
PubMed
6) Dries DL, et al : The prognostic imphcations of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35 : 681-689, 2000.
PubMed
7) Ghali JK, et al : Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. Arch Intern Med 148 : 2013-2016, 1988.
PubMed
8) Page J, Henry D : Consumption of NSAIDs and the development of congestive heart failure in elderly patients : an underrecognized public health problem. Arch Intern Med 160 : 777-784, 2000.
PubMed
9) Rockwood K : Acute confusion in elderly medical patients. J Am Geriatr Soc 37 : 150-154, 1989.
PubMed
10) Olofsson M, et al : Are elderly patients with suspected HF misdiagnosed? A primary health care center study. Cardiology 107 : 226-232, 2006.
PubMed
11) Redfield MM, et al : Plasma brain natriuretic peptide concentration : impact of age and gender. J Am Coll Cardiol 40 : 976-982, 2002.
 
12) Yamasaki N, et al : Heart failure in the elderly. Intern Med 42 : 383-388, 2003.
PubMed
P.561 掲載の参考文献
1) 石光敏行, 杉下靖郎 : 妊娠中の循環動態. 産婦人科の世界 49 : 409-415, 1997.
 
2) Robson SC, et al : Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol 256 : H1060-1065, 1989.
PubMed
3) Poppas A, et al : Serial assessment of the cardiovascular system in normal pregnancy. Circulation 95 : 2407-2415, 1997.
PubMed
4) 循環器病の診断と治療に関するガイドライン (2003-2004年度合同研究班報告) 心疾患患者の妊娠・出産の適応, 管理に関するガイドライン. Circ J 69 (Suppl IV) : 1267-1328, 2005.
 
5) Weiss BM, et al : Outcome of pulmonary vascular disease in pregnancy ; a systematic overview from 1978 through 1996. J Am Coll Cardiol 31 : 1650-1657, 1998.
PubMed

XXVI 特論

P.569 掲載の参考文献
1) Hersh WR, et al : Telemedicine for the Medicare population : pediatric, obstetric, and clinician-indirect home interventions. Evid Rep Technol Assess (Summ) (24 Suppl) : 1-32, 2001.
 
2) GESICA Investigators : Randomised trial of telephone intervention in chronic heart failure : DIAL trial. BMJ 331 (7514) : 425, 2005.
PubMed
3) Gregory D, et al : Hospital cost effect of a heart failure disease management program : the Specialized Primary and Networked Care in Heart Failure (SPAN-CHF) trial. Am Heart J 151 (5) : 1013-1018, 2006.
PubMed
4) Goldberger AL, et al : PhysioBank, PhysioToolkit, and PhysioNet : components of a new research resource for complex physiologic signals. Circulation 101 (23) : E215-220, 2000.
PubMed
5) Currell R, et al : Telemedicine versus face to face patient care : effects on professional practice and health care outcomes. Cochrane Database Syst Rev (2) : CD002098, 2000.
PubMed
6) Ross SE, et al : Providing a web-based online medical record with electronic communication capabilities to patients with congestive heart failure : randomized trial. J Med Internet Res 6 (2) : e12, 2004.
 
7) Salvador CH, et al : Airmed-cardio : a GSM and Internet services-based system for out-of-hospital follow-up of cardiac patients. IEEE Trans Inf Technol Biomed 9 (1) : 73-85, 2005.
PubMed
8) Artinian NT, et al : Pilot study of a Web-based compliance monitoring device for patients with congestive heart failure. Heart Lung 32 (4) : 226-233, 2003.
PubMed
9) Anliker U, et al : AMON : a wearable multiparameter medical monitoring and alert system. IEEE Trans lnf Technol Biomed 8 (4) : 415-427, 2004.
 
10) Barnason S, et al : Impact of a telehealth intervention to augment home health care on functional and recovery outcomes of elderly patients undergoing coronary artery bypass grafting. Heart Lung 35 (4) : 225-233, 2006.
PubMed
11) Cleland JG, et al : Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death : the Trans-European Network-Home-Care Management System (TEN-HMS) study. J Am Coll Cardiol 45 (10) : 1654-1664, 2005.
PubMed
12) Spaeder J, et al : Rapid titration of carvedilol in patients with congestive heart failure : a randomized trial of automated telemedicine versus frequent outpatient clinic visits. Am Heart J 151 (4) : 844. e1-10, 2006.
 
P.579 掲載の参考文献
1) Ross R : Atherosclerosis-An inflammatory disease. N Engl J Med 340 : 115-126, 1999.
PubMed
2) Luscher TF, Barton M : Biology of the endothelium. Clin Cardiol 20 : 3-10, 1997.
 
3) Node K, et al : Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285 : 1276-1279, 1999.
PubMed
4) Verma S, Anderson TJ : Fundamentals of endothelial function for the clinical cardiologist. Circulation 105 : 546-549, 2002.
PubMed
5) Perticone F, et al : Prognostic signhicance of endothelial dysfunction in hypertensive patients. Circulation 104 : 191-196, 2001.
PubMed
6) Ludmer PL, et al : Paradoxical vasoconstriction induced by acetylcholine in atherosclerotioc coronary arteries. N Engl J Med 315 : 1046-1051, 1986.
PubMed
7) Higashi Y, Yoshizumi M : New methods to evaluate endothelial function : method for assessing endothelial function in humans using a strain-gauge plethysmography : nitric oxide-dependent and -independent vasodilation. J Pharmacol Sci 93 : 399-404, 2003.
PubMed
8) Anderson TJ, et al : Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26 : 1235-1241, 1995.
PubMed
9) Corretti MC, et al : Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery : a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39 : 257-265, 2002.
PubMed
10) Widlansky ME, et al : The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42 : 1149-1160, 2003.
PubMed
11) Otsuka R, et al : Acute effects of passive smoking on the coronary circulation in healthy young adults. JAMA 286 : 436-441, 2001.
PubMed
12) Kato T, et al : Short-term passive smoking causes endothelial dysfunction via oxidative stress in nonsmokers. Can J Physiol Pharmacol 84 : 523-529, 2006.
PubMed
13) Laurent S, et al : Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37 : 1236-1241, 2001.
PubMed
P.587 掲載の参考文献
1) Nakagami T, et al ; DECODA Study Group. Diabetes Epidemiology : Collaborative Analysis of Diagnostic criteria in Asia ; International Diabetes Epidemiology Group : The fasting plasma glucose cut-point predicting a diabetic 2-h OGTT glucose level depends on the phenotype. Diabetes Res Clin Pract 55 (1) : 35-43. Erratum in : Diabetes Res Clin Pract 58 (1) : 73, 2002.
 
2) World Health Organization : Diabetes Mellitus, World Health Organization Technical Report Series, No 727, WHO, Geneva, 1985.
 
3) The Expert committee on the Diagnosis and Classification of Diabetes Mellitus : Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 22 (Suppl 1) : S5-S19, 1999.
 
4) Rajala U, et al : Prevalence of retinopathy in people with diabetes, impaired glucose intolerance, and normal glucose tolerance. Diabetes Care 21 : 1664-1669, 1998.
PubMed
5) Haffner SM, et al : Improved survival, reduced major coronary events and fewer revascularization in simvastatin-treated 4S patients with impaired fasting glucose (Abstract). Diabetes 47 : A54, 1998.
 
6) Minamino T, et al ; The J-WIND Investigators : Rationale and design of a Iarge-scale trial using nicorandil as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction : Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage by a K-ATP channel opener (J-WIND-KATP). Circ J 68 (2) : 101-106, 2004.
 
7) Asakura M, et al ; The J-WIND lnvestigators : Rationale and design of a large-scale trial using atrial natriuretic peptide (ANP) as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction : Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage by ANP (J-WIND-ANP). Circ J 68 (2) : 95-100, 2004.
 
P.593 掲載の参考文献
1) Asakura M, et al : Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF : metalloproteinase inhibitors as a new therapy. Nat Med 8 : 35-40, 2002.
PubMed
2) Yamazaki S, et al : Mice with defects in HB-EGF ectodomain shedding show severe developmental abnormalities. J Cell Biol 163 : 469-475, 2003.
PubMed
3) Iwamoto R, et al : Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci USA 100 : 3221-3226, 2003.
PubMed
4) Feldman AM, et al : Trastuzumab in the treatment of metastatic breast cancer : anticancer therapy versus cardiotoxicity. Circulation 102 : 272-274, 2000.
PubMed
5) Bahar R, et al : Increased cell-to-cell variation in gene expression in ageing mouse heart. Nature 441 : 1011-1014, 2006.
PubMed
6) Asano Y, et al : Lamr1 functional retroposon causes right ventricular dysplasia in mice. Nat Genet 36 : 123-130, 2004.
PubMed
7) Spalding KL, et al : Retrospective birth dating of cells in humans. Cell 122 : 133-143 2005.
PubMed
P.600 掲載の参考文献
1) Rose EA, et al : Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 345 : 1435-1443, 2001.
PubMed
2) Yamazaki K, et al : EVAHEART : an implantable centrifugal blood pump for long-term circulatory support. Jpn J Thorac Cardiovasc Surg 50 : 461-465, 2002.
PubMed
3) Yamazaki K, et al : An implantable centrifUgal blood pump with a recirculating purge system (Cool-Seal system). Artif Organs 22 (6) : 466-474, 1998.
PubMed

書評

最近チェックした商品履歴

Loading...